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7SUMMARY
The machinery that generates the daily temporal organization of the body functions is collectively
known as the circadian clock and the output of the clock is called circadian rhythms. The clock
generally requires daily resetting by external time cues. The dominant synchronizing signal for the
rhythmicity is provided by the light-dark cycles of a 24-hour solar day. One of the most clearly
fluctuating functions is melatonin secretion from the pineal gland. Photic information is transmitted as
multisynaptic neural inputs by the central nervous system via periferal nerves to the pineal gland.
Melatonin is secreted rhythmically with increased synthesis during the dark period of the day.
Light has dual effects on melatonin secretion: it decreases melatonin levels acutely and shifts the phase
of the melatonin rhythm. In the present investigations, light-induced changes in the level and rhythm of
melatonin were investigated in order to examine the importance of light in the regulation of human
circadian rhythms.
In the first study, a bright light exposure was found effective in suppressing melatonin secretion in
blind neuronal ceroid lipofuscinosis patients with degenerated retinas. This result indicates that an
intact retina is not required for the transmission of light to the hypothalamus or for the regulation of
neuroendocrine functions.
In the second study, a bright light exposure induced a decrease in melatonin concentrations only in a
minority of volunteers with closed eyelids. Together with other studies, this finding suggests that the
eyes are in a dominate role in the transduction of photic information to the circadian system, and
closed eyelids (e.g. during sleep) can significantly limit the hypothalamic effects of light.
In the third study, a bright light pulse of relatively low intensity and short duration induced an
interruption of melatonin secretion and shifted the phase of the melatonin rhythm. Thus, melatonin acts
as a sensitive marker of environmental lighting even in artificial indoor conditions.
In the fourth study, a bright light pulse during the rising phase of the melatonin synthesis delayed the
melatonin rhythm irrespective of concomitant placebo or melatonin administration. This indicates that
suppression of melatonin is not essential for the phase shifting mechanisms of light.
Not long ago it was thought that light had no impact on the circadian rhythms in humans. The present
findings together with other studies indicate that light is the primary external cue regulating our
circadian functions. Melatonin acts as a reliable neuroendocrine messenger of environmental lighting
conditions, but the phase shifting effect of light on circadian rhythms can be independent of the
melatonin concentration in the circulation.
8INTRODUCTION
All biological functions, in cells, tissues, organs and the entire body, run on a cycle of alternating
activity and rest. In the world of science, this relatively new discipline is termed chronobiology,
meaning that time-related events shape our daily physiological responses.
The rhythms of biological functions with a period of approximately 24 hours are called circadian
rhythms (Latin, circa=about, dies=a day). Most of these rhythms are under the control of an internal
clock. This timepiece is affected by events in the environment, and especially by the light-dark cycle.
Besides its function in vision, light has a fascinating role in the modulation of the circadian rhythms.
One of the well-known action of light is its dual effects on pineal neurohormone melatonin synthesis:
light decreases melatonin levels acutely and shifts the phase of the melatonin rhythm.
Researchers all over the world try eagerly to find out the physiological importance of melatonin in the
human body. In mass media, melatonin has been introduced as a life-giving miracle agent. At the
moment, indications for melatonin treatment are lacking. The long-term adverse effects of exogenous
melatonin are not known, and its use has not been proven safe by usual clinical trial criteria either.
The best-described action of melatonin is its function as a circadian marker and chemical expression of
darkness. Light and melatonin may serve complementary effects: light provides a daytime and
melatonin a nighttime signal to an organism. Indeed, light could be an exogenous timing agent and
melatonin an endogenous one. However, there is still a lot to be learned about melatonin's role in
neuroendocrine phototransduction and its interaction with light and dark alterations in humans.
The topic of this thesis was chosen with physiological aspects of light and melatonin in view. The
present series of investigations focuses on the regulation of human melatonin by light, and light-
induced changes in the secretion of the hormone were performed in order to shed light on the
mechanisms underlying this phenomen.
9REVIEW OF THE LITERATURE
CIRCADIAN RHYTHMS
The French astronomer Jean Jacques d’Ortous de Mairan discovered in 1729 that when a Mimosa
plant was placed in the constant darkness of a closet, the opening and closing of the leaves still
occurred on the basis of an intrinsic rhythm (de Mairan 1729, referred by Meijer & Rietveld 1989).
Thus, he pointed out for the first time the independence of biological rhythms of the light-dark cycle.
All organisms generally have the capacity for endogenous temporal organization of biological
processes over the course of day. The cellular, neural and humoral machinery that generates this ability
is collectively known as the biological clock. This timing device functions as a pacemaker of a
complex oscillation network. The endogenous period of the clock is not exactly 24 hours. Thus, the
clock generally requires daily resetting by external time cues. This process is called entrainment.
The output of the pacemaker is called circadian rhythms. These rhythms have two principal properties:
they are normally entrained to external time cues, but in the absence of synchronizing signals, they
free-run with a period slightly different from 24 hours (Aschoff 1965a). The light-dark (LD) cycle of a
24-hour solar day is the main environmental cue entraining the clock and the rhythms driven by it.
The existence of a circadian or daily rhythm is apparent in physiological, pharmacological and
pathological events and parameters. These include physical activity, body temperature, plasma levels
of hormones (e.g. cortisol, renin, angiotensin, aldosterone, noradrenaline, insulin, prolactin, growth
hormone, thyrotropin, atrial natriuretic peptide, vasopressin), response to a glucose-tolerance test,
performance variables (e.g. reaction time, reading error, subjective alertness, working memory speed,
self-chosen work-rate), birth and death rate, pharmacokinetics and effects of drugs, and risk for
cardio- and cerebrovascular attacks (Wever 1979, Reilly et al. 1997, Schwartz 1997, Lemmer 1999).
Moreover, various functions of the heart and circulation (e.g. cardiac output, heart rate, blood
pressure), of the respiratory system (e.g. minute volume, oxygen consumption, carbon dioxide
production) and of the kidneys (e.g. glomerular filtration rate, urine flow rate, electrolyte excretion)
can vary with the time of day  (Wever 1979, Reilly et al. 1997).
In addition to the action of light on the period of the circadian rhythms, light exposures are able to
affect the phase of the rhythms. There are three possible effects: no shift, delay, or advance. The
magnitude and direction of the phase shift depend on the phase of the rhythm at the time of stimulus
application. This relationship can be illustrated by a phase-response curve (Aschoff 1965b).
Temporal regulation of behavioral and internal homeostatic events is a fundamental feature of
mammalian adaptation. It helps to optimize the economy of biological systems, and prepares an
organism to foresee and cope with the 24-hour solar day resulting from the rotation of our planet.
Although normally the biological clock and the rhythms driven by it are entrained by environmental
time cues, in certain situations the rhythms are not synchronized with the time cues (external
desynchronization) or with each other (internal desynchronization). For example, time zone
transitions, night work or blindness may cause deficient entrainment and desynchronized circadian
rhythms, namely circadian disorders. 
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CIRCADIAN TIMING SYSTEM
In vertebrates, the master biological clock system is located in the hypothalamic suprachiasmatic
nucleus (SCN). The paired nucleus consists of thousands of neurons, for instance in rats of about 8000
neurons occupying 0.07 mm3 and in humans of about 10 000 neurons occupying 0.25 mm3 (van den
Pol 1980, Swaab et al. 1993, Hastings 1997). In humans, the SCN is situated on either side of the
brain midline on the top of the optic chiasma and about 3 cm behind the eyes in the basal part of the
anterior hypothalamus. The SCN is involved in the generation and expression of physiological
functions with circadian properties. These include e.g. water and food intake, motor activity, sleep-
wake rhythm, corticosterone release, activity of pineal N-acetyltransferase enzyme, and body
temperature (reviewed by Rusak & Zucker 1979). In addition, lesions of the SCN abolish the
nocturnal increase of melatonin synthesis (Reppert et al. 1981, Lehman et al. 1984, Kalsbeek et al.
1996).
The circadian timing system consists of three essential components: entrainment pathways (inputs),
oscillation mechanisms generating the rhytmicity (pacemaker) and efferent pathways mediating the
expression of circadian rhythms (output).
Input pathways
The best-described entrainment pathways to the SCN originate in retinal ganglion cells. The
retinohypothalamic tract (RHT) is the main route responsible for photoentrainment (Hendricson et al.
1972, Moore & Lenn 1972). The RHT originates from a distinct and homogenous group of ganglion
cells (Moore et al. 1995). It leaves the optic nerve mainly in the anterior part of the optic chiasm and
terminates predominantly within the ventrolateral part of the SCN (Levine et al. 1991, Speh & Moore
1993, Reuss 1996). It has been shown that the RHT has several components; the largest projects to
the SCN, but there are additional projections to the lateral and anterior hypothalamic area, and to the
retrochiasmatic area which is a complex zone immediately caudal to the SCN (Johnson et al. 1988b).
Glutamate appears to be the main transmitter of the RHT (de Vries et al. 1993, Shirakawa & Moore
1994, Mintz et al. 1999).
The retinal pathway responsible for the projection of the circadian system to the SCN branches off the
projection to the visual centers of the brain (Klein & Moore 1979, Moore et al. 1995). In fact, the
section of visual pathways beyond the RHT does not affect stable entrainment (Klein & Moore 1979),
whereas ablation of the RHT (Johnson et al. 1988a) or blinding (Wurtman et al. 1964, Klein & Weller
1970, Klein & Weller 1972, Nelson & Zucker 1981, Lucas & Foster 1999) results in the loss of the
ability of light to entrain circadian rhythmicity.
In addition to the RHT, the SCN also receives input from the intergeniculate leaflet (IGL), raphe
nuclei, the paraventricular thalamus and the limbic telencephalon (reviewed by Moga & Moore 1997).
The pathway via the IGL (Pickard 1985) of the lateral geniculate complex of the thalamus through the
geniculohypothalamic tract (Rusak et al. 1993, Moore & Card 1994) to the SCN is suggested to
modulate photic and nonphotic information to the circadian system (Johnson et al. 1989, Moore &
Card 1994, Moga & Moore 1997). In this tract, gamma-aminobutyric acid, neuropeptide Y and
enkephalin are likely candidates for being the chemical transmitters (Moore & Speh 1993, Moga &
Moore 1997). Midbrain raphe nuclei also project to the SCN (Rusak et al. 1993, Miller et al. 1996)
and serotonergic input from these nuclei is suggested to play a role in the circadian system, but not to
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be primarily involved in the entrainment to the LD cycle (Meijer & Rietveld 1989, Meyer-Bernstein &
Morin 1999). The spesific functions of the thalamus, the limbic region and other unexplored tracts in
the circadian timing machine await clarifying.
Evidence for the pacemaker in the suprachiasmatic nucleus
The late Curt Richter deserves the credit for pinpointing the hypothalamus as the home of the
biological clock, even though he did not specifically identify the SCN. Richter (1967) investigated the
function of the hypothalamus by making lesions, and he discovered that lesions in the region of the
ventral median nucleus eliminated eating and drinking rhythms in rats.
The SCN seems not to be just a simple hourglass timer directly driven by external signals. In addition
to the SCN being the major site for the RHT input, there are five lines of evidence indicating that the
SCN acts as a circadian pacemaker. First, ablation of the SCN eliminates circadian functioning as
shown originally by two teams of investigators working independently. Moore and Eichler (1972)
found that SCN lesions destroyed circadian adrenal corticosterone rhythms in the rat, and that in the
absence of the SCN not even the preservation of the optic tracts was sufficient to maintain
synchronization. In the same year, Stephan and Zucker (1972) demonstrated that electrolytic lesions in
the SCN permanently eliminated circadian rhythms of drinking behavior and locomotor activity of the
rats.
The second line of evidence suggesting a pacemaker function for the SCN comes from the studies in
which circadian functioning was found to be maintained in isolated SCN, both in vivo (Inouye &
Kawamura 1979) and in vitro (Shibata & Moore 1988). In addition, Green and Gillette (1982)
showed that single cells, removed from the SCN and put in culture, could persist in their rhythms for
up to 60 hours.
Third, electrical stimulation of the SCN in hamsters and rats resulted in phase-dependent shifts of the
free-running activity cycle (Rusak & Groos 1982). Phase-shifting effects are also observed after local
stimulation of the SCN with a cholinergic agonist, glutamate, or a glutamate agonist (Zatz &
Herkenham 1981, Meijer et al. 1988, Mintz & Albers 1997).
The fourth line of evidence for the role of the SCN as a pacemaker is provided by the findings on the
circadian rhythm of metabolic activity in the SCN. Indeed, in the absence of periodic environmental
light cues, glucose utilization of the nucleus was found to be high during the subjective day and low
during the subjective night (Schwartz et al. 1980, Reppert & Schwartz 1984).
Fifth, transplantation of the fetal anterior hypothalamus containing the SCN into the third ventricle of
arrythmic, SCN-lesioned animals was demonstrated to restore rhythmicity (Lehman et al. 1987);  the
period of the restored rhythm being determined by the graft (Ralph et al. 1990).
Mechanisms of the pacemaker in the suprachiasmatic nucleus
There is no point having a watch unless it keeps time. The timekeeping mechanisms underlying the
oscillating action of the SCN have been the focus of many recent studies. To date, molecular clock
models of similar structure have been proposed for cyanobacteria, fungi and animals, but the key
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proteins for these models do not share sequence similarity (Dunlap 1999). Thus, it appears likely that
the clock systems have developed independently in different organisms, and by alternating
environment natural selection has apparently led to the evolvement of clock systems which have only
some physiological properties in common (reviewed by Kondo & Ishiura 1999).
The fruit fly Drosophila has autonomous circadian clocks throughout the body (Plautz et al. 1997),
suggesting that individual cells are capable of supporting their own independent clocks. In mammals,
however, experimental findings suggest that SCN neurons are born as circadian oscillators coupled
within the nucleus to form a complex network pacemaker (Moore & Bernstein 1989). Support for this
hypothesis is provided by the observations that the SCN contains many autonomous, single-cell
circadian oscillators (Welsh et al. 1995), that isolated glands and pieces of tissue can continue to show
circadian oscillations in culture (reviewed by Takahashi & Zatz 1982) and that various rhythms of an
organism sometimes free-run with different circadian periods during constant environmental
conditions (Wever 1979, Turek et al. 1982). In addition, this hypothesis of a multioscillator system is
supported by the report of Moore-Ede (1983) as well as by the study of Illnerová and Vanecek
(1982), indicating a two-oscillator pacemaking system with an evening oscillator coupled to dusk and
a morning oscillator coupled to dawn.
Indeed, the light-induced immediate increase in the multiple unit activity of SCN neurons was found to
be independent of the timing of the exposure (Inouye 1984), whereas the shift of the activity of the
neurons was found to be depend on the timing of the exposure (Inouye & Kawamura 1982). Thus,
while the direct effect of a light stimulus at the input side of the SCN shows no circadian variation, the
output of the SCN shows circadian variation, indicating that the state and internal process of the
pacemaker dictate the outcome of the circadian event.
In addition, researchers are trying to assign molecular clock components by investigating different
genes involved in or capable of affecting the operation of the biological clock. Until 1997, clock
researchers had only three clock components to work on: two proteins from a fruit fly (Drosophila)
and one from a bread mold (Neurospora) (reviewed by Dunlap 1999). Takahashi and coworkers
(Antoch et al. 1997, King et al. 1997) demonstrated the existence of the first mammalian clock gene,
Clock, from mice. In addition, common elements of oscillation are likely to be present up and down
the evolutionary tree. For instance, in the mouse there are three different gene relatives (Per1, Per2
and Per3) that are related to the Drosophila per gene (reviewed by Dunlap 1999). Transcription of
clock genes and synthesis of the proteins they encode form the basis of the timekeeping function.
Interactions among these proteins result in feedback inhibition of gene transcription. With degradation
of the protein products, gene transcription is again initiated to reestablish the cycle (Dunlap 1999). The
major elements of the cycle have been identified, but exact functional roles of the molecular
components await revealers.
Output pathways
The function of the different projections of the pacemaker and transmitters communicating circadian
information to the rest of the brain is not well understood. In addition, the morphological organization
of SCN projections is rather difficult to study because of technical difficulties combined with the very
small size of the SCN. The human SCN can be apportioned into five chemoarchitectonic subdivisions
of different kinds of neurons (Mai et al. 1991); vasopressin and vasoactive intestinal polypeptide
containing neurons are the common ones in the human SCN (Hofman et al. 1996, Dai et al. 1997).
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Efferent projections leave the SCN via ventrocaudal, lateral, dorsal and rostral pathways (Stephan et
al. 1981) and many of these projections terminate in other hypothalamic nuclei as well as in the
thalamus and midbrain (Berk & Finkelstein 1981) in rats. On the basis of immunological studies, there
is general agreement that the SCN project to a number sites in the basomedial hypothalamus and the
midline thalamus in rodents (Watts et al. 1987, Watts & Swanson 1987, Kalsbeek et al. 1993). In
humans, the efferent projections of the SCN appear to be comparable to those described in rats and
hamsters (Dai et al. 1998). The human SCN was found to be connected with the nuclei in the
hypothalamus that are involved in hormone secretion, cardiovascular regulation and integration of
autonomic information. It is suggested that through these projections the SCN may influence brain
areas that regulate e.g. thirst, food intake, metabolism, sleep, sexual behavior, and body temperature
(reviewed by Dai et al. 1998).
The best-described efferent pathway of the SCN emerges from the pineal gland. This route from the
SCN runs via the paraventricular nucleus (PVN) of the hypothalamus, the intermediolateral cell
column of the spinal cord, the superior cervical ganglion, and sympathetic efferents to the pineal gland
(Moore 1996).
CIRCADIAN PHOTORECEPTION
The visual and circadian light detection systems have been shown to differ from each other (Chase et
al. 1969, Frost et al. 1979). Eyes provide the primary source of circadian photoreception because eye
loss in both humans and other mammals abolishes photoentrainment (Wurtman et al. 1964, Klein &
Weller 1970, Klein & Weller 1972, Nelson & Zucker 1981, Lucas & Foster 1999). However, the
nature of the photoreceptors that provide input from the retina to the circadian timekeeping system
remains elusive.
Retinal photoreception
Originally, orthodox photoreceptor cells, i.e. retinal rods and cones capturing light for vision, were
thought to represent also the photoreceptive elements in light-to-circadian-clock transmission. The
light sensitivity of the mammalian pineal gland has been demonstrated with single cell recordings to be
contributed by both rods and cones (Thiele & Meissl 1987). On the other hand, it was suggested that a
rhodopsin-like pigment mediate circadian vision, because both the spectral sensitivity of the phase-
shifting effect and the suppression of pineal N-acetyltransferase enzyme by light resemble the
absorption spectrum of the pigment (Takahashi et al. 1984, Bronstein et al. 1987). These studies are
in line with the study on the wavelength sensitivity of melatonin suppression in humans (Brainard et al.
1985) reporting that rods arbitrate the effects of light in the mammalian circadian timing system.
More recently, studies in strains of mice with hereditary retinal degeneration suggest that the
hypothalamic effects of light might be mediated rather by the remaining fragments of cone
photoreceptors than by rods (Provencio et al. 1994, Lucas & Foster 1999). In a study by Rutkowska
and colleagues (1998), the rhythm of core temperature in color-deficient subjects was found to be
phase-delayed as compared with normal sighted subjects, suggesting a role of retinal cones in the
mediation information between environment and the circadian clock. On the other hand, in aged mice,
circadian responses to light do not correlate with the number of surviving cones (Provencio et al.
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1994), and at least in humans, a normal trichromatic visual system is not necessary for light-mediated
melatonin regulation (Ruberg et al. 1996).
It has been suggested that there may be some unidentified retinal light-sensitive cells that send
information to the lower brain centers (Foster et al. 1993, Provencio et al. 1994, Huerta et al. 1999,
Lucas & Foster 1999). In a strain of retinally degenerate mice with remaining but high-threshold
circadian responses to light, the spectral sensitivity of the phase-shifting effect was different from the
sensitivity of sighted animals, indicating that various photopigments may be involved in the response
(Yoshimura & Ebihara 1996). More recently, it has been shown that neither rods nor cones are
required for light-induced melatonin suppression (Lucas et al. 1999) or for photoentrainment of
wheel-running activity (Freedman et al. 1999) in mice. In addition, Provencio and coworkers (2000)
have identified a novel human opsin which is expressed in cells of the inner retina, but not in retinal
photoreceptor cells involved in image formation. The question remains whether there are still
uncharacterized photoreceptors in the retina for the transduction of light stimulus to the circadian
system.
Besides the studies conducted on opsin/retinal-based photopigments, the possible involvement of
cryptochrome blue-light photoreceptors in circadian photic responses has recently become a topic of
interest. Cryptochrome proteins are light-sensitive, putative vitamin-B2 based pigments, and
cryptochromes 1 and 2 are expressed in the mouse retina and SCN (Miyamoto & Sancar 1998). The
observation that the expression of cryptochrome 1 gene exhibits circadian oscillations in the mice SCN
(Miyamoto & Sancar 1998) proposes that cryptochromes have a role in circadian photoreception in
mammals. Recently, it was shown that the mammalian cryptochrome 1 and 2 are essential for the
circadian clockwork (van der Horst et al. 1999). However, the cryptochrome 1 and 2 genes are not
essential for the light-induced phase shifting of the clock (Thresher et al. 1998, Okamura et al. 1999).
Extraocular photoreception
Extraocular photoreceptors are capable of providing sufficiently light to the circadian timing system in
nonmammalian vertebrates (Underwood & Groos 1982, Yoshikawa & Oishi 1998), and some
researchers have also demonstrated nonocular photoreception in mammals. For instance, the neonatal
rat pineal has been shown to be photosensitive (Blackshaw & Snyder 1997) and extraretinal
mechanisms are reported to mediate light-induced changes in the regulation of pineal N-
acetyltransferase enzyme in newborn rats blinded by bilateral orbital enucleation (Torres & Lytle
1989). In addition, other investigators have obtained evidence suggesting that light can directly affect
hypothalamic neurons in enucleate adult rats (Lisk & Kannwischer 1964).
In 1998, a surprising finding about nonocular phototransduction in humans was reported. The results
of this study suggested that a bright light exposure to the back of the knee could phase shift human
body temperature and melatonin secretion rhythms without any transmission of light through the eyes
(Campbell & Murphy 1998). A photosensitive property of the skin has also been proposed by the
finding that the LD alterations synchronize melatonin levels in genetically mutant anophthalmic rats
lacking a complete visual system (Jagota et al. 1999).
One possible mechanism for extraocular photoreception has been attributed to chronobiological
photoreceptors in blood (Oren & Terman 1998). In fact, Oren (1996, 1997) has hypothesized that
heme moieties and bile pigments contained by blood could serve as photoreceptors. This humoral
phototransduction model postulates that tetrapyrrole-based pigments, e.g. primary light-sensitive plant
15
pigments of chlorophyll and phytochrome, and mammalian hemoglobin and bilirubin, mediate light-
induced circadian effects.
The skin is an interesting candidate for being a photoreceptive element. Two research reports of
Iyengar (1994, 1998) have suggested that the melanocyte network in cultured human skin senses light,
indicating that cells in the skin might be able to take part in chronobiological events.
In contrast to the above studies on nonocular phototransduction, an earlier study by Nelson and
Zucker (1981) demonstrated that the activity rhythms of blinded diurnal ground squirrels and
nocturnal grasshopper mice failed to entrain to the LD cycle. In line with this, the study in bilaterally
anophthalmic rats showed no evidence of extraocular photoreception (Ibuka 1987). Recent studies by
Meijer and coworkers (1999) and Yamazaki and associates (1999) report that illumination of the skin
of blinded and shaved hamsters did not result in phase shifting effects on activity rhythms. In addition,
light responsiveness of metabolic activity and gene expression of the SCN have been found to be
mediated only through the eyes in preterm infant baboons (Hao & Rivkees 1999). Indeed, the absence
of nonocular photic regulation of the circadian rhythms in humans has been suggested by our recent
study indicating that a bright light exposure on the skin of the abdomen and chest does not induce
phase shifting of melatonin, cortisol and thyrotropin rhythms (Lindblom et al. 2000).
Although a phase shifting effect of extraocular light exposure on the melatonin rhythm has been
suggested (Campbell & Murphy 1998), there is no evidence of suppression of melatonin levels by skin
illumination either in humans (Lockley et al. 1998, Hébert et al. 1999, Lindblom et al. in press) or
hamsters (Yamazaki et al. 1999).
It seems that there are still discrepancies in the findings on the photoreceptive elements of circadian
events. Several possible mechanisms and pathways could be involved in the effect that light has on the
melatonin synthesis and other circadian rhythms. In conclusion, more research is needed before the
nature of retinal photoreceptors and the role of extraocular phototransduction in the function of the
circadian timing system are solved.
LIGHT AND THE DAILY RHYTHMS
The visible portion of the electromagnetic spectrum covers the wavelength range from 380 to 760 nm,
and the eye discriminates between different wavelengths within this range by sensation of color. Light
is used to generate a visual image of the environment and to provide time-of-day information. In
addition to the timing effects of light on the circadian system, light has also some direct neural effects.
For instance, light exposures are able to increase body temperature (Strassman et al. 1991), enhance
alertness (Campbell et al. 1995) and suppress melatonin (Brainard et al. 1997).
Light as a synchronizer of the circadian timing system
A temporal structure is needed for circadian timekeeping. The internal circadian clock generally
requires daily resetting by external time cues (Wever 1979, Czeisler et al. 1980). Several
environmental and behavioral stimuli have been shown to act as circadian synchronizers. These include
the timing of food availability, social interaction and physical activity (Stephan 1981, Mrosovsky &
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Salmon 1987, Mrosovsky et al. 1989, Van Reeth & Turek 1989, Edgar & Dement 1991, Marchant &
Mistlberger 1996).
However, in animals the dominant synchronizing signal for circadian rhythmicity is provided by
environmental LD cycles. In many species of animals, light plays an important role in the regulation of
circadian rhythms, e.g. motor activity, hormone secretion and temperature (McGuire et al. 1973,
Wurtman 1975, Elliott 1976). Phase response curves (PRCs) are constructed by exposing the
organism to an external signal or by administering a compound at different phases of the endogenous
rhythm and measuring the resulting effect on the phase of the cycle (Aschoff 1965b). The first PRC to
light was demonstrated by DeCoursey (1960) 40 years ago in flying squirrels. In 1978, Honma and
associates (1978) reported the PRC of the locomotor activity rhythm to light pulses in rats which
showed that phase delays occurred in the early subjective night followed by phase advances.
The influences of light and darkness on circadian rhythms can also be demonstrated by studies
conducted in constant environmental lighting conditions. In constant darkness the rhythms free-run in
rats (Redman et al. 1983, Thomas & Armstrong 1988). Continuous light treatment induces
suppression of melatonin biosynthesis (Klein & Weller 1970, Laakso et al. 1994a) and the circadian
rhythmicity of locomotor activity is lost (Honma & Hiroshige 1978, Chesworth et al. 1987) in rats.
Several other circadian rhythms in rats (e.g. behavioral, temperature and some humoral rhythms) may
persist for several weeks depending on the intensity of light (Honma & Hiroshige 1978, Eastman &
Rechtshaffen 1983, Deprés-Brummer et al. 1995).
Based on current knowledge, the circadian rhythms of humans are also sensitive to light, although
earlier findings of temporal isolation experiments proposed that social contacts are more effective than
light in the entrainment of human circadian rhythms (Wever 1979). Indeed, as early as in 1960,
support for the capacity of light and darkness to synchronize the human circadian system was provided
by Sharp (1960) who reported a phase delay in the plasma levels of leucocytes in response to
extension of darkness following normal wake time. A similar kind of finding was reported by Orth and
Island (1969) and by Osterman (1974), who demonstrated that the circadian rhythm of plasma
corticosteroids could be phase shifted by prolongating the dark period of the day.
In addition, more recent studies have shown that the effects of a single light pulse on the phase of
human circadian rhythm markers can be observed after only a single day (Honma et al. 1987,
Burešová et al. 1991, Minors et al. 1991, Van Cauter 1994) and in primates effective entrainment can
be induced by a 1-s light pulse (Sulzman et al. 1981). In fact, the importance of the LD cycle in human
circadian resetting was shown in the study of Czeisler and associates (1981) and Middleton and
coworkers (1996a) underlining the lesser role of social cues and knowledge of clock time.
In humans, light has been found to be a stronger synchronizer of circadian rhythms than the sleep-
wake rhythm. For instance, light-induced phase shifts of body temperature, cortisol, melatonin and
sleep propensity rhythms could be seen even when the timing of the sleep-wake cycle was held
constant (Czeisler et al. 1986, Drennan et al. 1989, Dijk et al. 1987, Lewy et al. 1987, Dijk et al.
1989). Clodoré and associates (1990) and Foret and coworkers (1993) have reported that the rhythms
of cortisol, alertness and performance can be phase advanced by repeated morning exposure to bright
light.
The theoretical basis of the PRC to light in humans was postulated by Lewy and collaborators (1983).
The first contribution toward the findings of light-induced phase advances and delays were provided
by Honma and colleagues (1987) who showed that phase shifts of both sleep-wake and temperature
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rhythms could be induced by a bright light pulse. In 1989, the PRC to a non-24-hour LD cycle for
body temperature was demonstrated (Wever 1989). More recently, Minors and coworkers (1991),
Dawson and colleagues (1993) and Van Cauter and associates (1994) established the human PRCs to
single bright light pulses for body temperature, melatonin and thyrotropin rhythm (Figure 1). In
addition, a strong resetting of the human circadian timing system by multiple light pulses has been
demonstrated (Czeisler et al. 1989, Shanahan et al. 1999).
Together, circadian PRCs produced in response to light have been found to share the following time-
dependent properties: light stimuli early in the subjective night induce phase delay shifts, light stimuli
late in the subjective night induce phase advance shifts, and light stimuli during the subjective day
induce no or minimal phase shifts (Figure 1). Dose-response relationships have also been established
between light intensity and phase shifting of the human temperature rhythm (Boivin et al. 1996).
Constant environmental lighting conditions also influence the circadian rhythms in nonhuman primates
and humans. For instance, in many blind people the circadian rhythms free-run (Miles et al. 1977, Orth
et al. 1979, Smith et al. 1981, Lewy & Newsome 1983, Nakagawa et al. 1992, Sack et al. 1992b,
Klein et al. 1993, Skene et al. 1999). In the sighted, the period of human melatonin, body temperature
and cortisol rhythms has been demonstrated to average 24.18 hours in controlled conditions of low
light levels (Czeisler et al. 1999). Continuous light treatment induces suppression of melatonin
rhythms in primates (Perlow et al. 1980, Perlow et al. 1981, Tetsuo et al. 1982). On the other hand,
constant light conditions have variable disturbing effects on other circadian rhythms. For instance, the
daily rhythmicity of cortisol and urinary potassium excretion in humans (Krieger et al. 1969) and
cortisol secretion in primates are not altered (Perlow et al. 1981) in constant illumination.
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Figure 1. SCHEMATIC HUMAN PHASE-RESPONSE CURVES TO LIGHT AND MELATONIN.
The y-axis of the phase-response curve (PRC) shows the direction and relative magnitude of the phase shift of the
body temperature rhythm induced by light exposure (—) and the phase shift of the melatonin rhythm produced by
melatonin administration (…) at various times shown on the x-axis as local or circadian times. The circadian
time 18 corresponds roughly to the minimum of the body temperature. The black bar indicates a typical time for
sleep relative to the minimum of the body temperature when the circadian system is entrained to the 24-hour day.
For orientation purposes, sunrise and sunset are drawn in for the time of year when the night and day are of
equal length. The PRC to light is about 12 hours out of phase with the PRC to melatonin (modified from Minors et
al. 1991, Lewy et al. 1998a, Eastman & Martin 1999).
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MELATONIN AND THE PINEAL GLAND
Over two millennia ago, Herophilos (325-280 B.C.), who was a famous anatomist at the University of
Alexandria in Egypt, was probably the first reseacher to discover the pineal organ in humans. Nothing
is left of his writings, which have been cited by a Greek physician Galen (±130-300 A.D.). Galen
termed the pineal konareion (Latin, conarium) after its pineconelike shape, and described its possible
glandular function (reviewed by Kappers 1979).
In the 17th century, the French philosopher and mathematician René Descartes (1596-1650) regarded
the pineal organ as the soul's right hand, meaning that the soul exercises its functions to a great degree
in the unpaired pineal organ. He likened pineal functions to a valve that regulates the direction and
volume of the animal spirits flowing to and from the brain. Thus, he suggested that the pineal initiates
the motor stimulus by sending the spirits into the tubular motor nerves (reviewed by Kappers 1979).
In 1917, McCord and Allen (1917) demonstrated that extracts of the pineal gland cause the skin of
tadpoles to lighten. A major breakthrough in pineal studies occurred in 1958 when the dermatologist
Aaron Lerner and coworkers (1958) extracted bovine pineal glands and were able to isolate a skin
lightening compound, and determine its structure (1959) after 4 years of work and the use of more
than 250 000 pineal glands (Lerner 1999). The compound was called melatonin (Greek, melas=black
and tosos=labor). Axelrod and associates (Axelrod & Weissbach 1960, Weissbach et al. 1960,
Weissbach et al. 1961) demonstrated that melatonin could be synthesized within the pineal gland. In
later studies, in which it was shown that pinealectomy abolished the circadian rhythm of melatonin, it
was confirmed that the pineal gland is the main source of melatonin in rats (Ozaki & Lynch 1976,
Lewy et al. 1980a), rhesus monkeys (Tetsuo et al. 1982) and humans (Neuwelt & Lewy 1983,
Petterborg et al. 1991).
The pineal gland (Latin, epiphysis cerebri, glandula pinealis) is a part of the brain derived from the
caudal portion of the embryonic dorsal diencephalic cell column, the epithalamus. The morphology of
the pineal changes dramatically with phylogenetic development. In mammals, the pineal has lost
virtually all of its photoreceptor elements and instead contains parenchymal cells whose appearance
suggests an entirely secretory function (Korf & Oksche 1986). According to current knowledge, the
mammalian pineal (weight, 100 mg in humans, 1 mg in rats; Axelrod 1974) is considered a
neuroendocrine organ. In humans, it is located at the posterior wall of the third ventricle near the
geometric center of the brain. In addition, different indoleamines, including melatonin, and also several
peptides are found in the pineal (Vaughan 1984, Ebels & Balemans 1986).
Previously, a widely held view was that the human pineal is a calcified vestigial organ which provides
only a useful landmark for neuroradiologists. According to present knowledge, the physiological
significance of the pineal gland in humans is mainly related to the function of melatonin. Melatonin is
regulated by the circadian timing system, and LD cycles control the timing of melatonin secretion.
Indeed, elevated melatonin levels are associated with nighttime, and melatonin has become to be
known as the chemical expression of darkness (Reiter 1991a). In addition to the function of melatonin
as a marker of environmental lighting conditions, melatonin may have some other physiological effects
e.g. on reproduction and immune system.
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Figure 2. THE REGULATION PATHWAY OF THE PINEAL MELATONIN.
Sagittal view of human brain showing the pineal and its innervation. Retinohypothalamic fibers synapse in the
suprachiasmatic nuclei (SCN), and there are connections from the SCN to the intermediolateral gray column in
the spinal cord. Preganglionic neurons pass from the spinal cord to the superior cervical ganglion (SCG), and
the postganglionic neurons project from this ganglion to the pineal in the nervi conarii (modified from Ganong
1997).
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The regulation of pineal melatonin
Synthesis of melatonin
Melatonin is a small (molecular weight 232.3) indoleamine secreted rhythmically with increased
synthesis during the dark period of day. Alterations in environmental lighting are signaled as
multisynaptic neural inputs by the central nervous system via periferal nerves into a hormonal output
of the pineal gland (Figure 2). In mammals, circadian photoreceptors of the retina convert light and
darkness into signals that are sent directly to the SCN through the main pathway, the RHT
(Hendrickson et al. 1972, Moore & Lenn 1972).
From the SCN, neuronal projections make synaptic connections in the PVN of the hypothalamus
descending onward through the medial forebrain bundle to the intermediolateral cell column of the
spinal cord from where preganglionic fibers reach the superior cervical ganglia (Swanson & Cowan
1975, Saper et al. 1976, Rando et al. 1981, Moore 1996). Sympathetic postganglionic noradrenergic
fibers from the superior cervical ganglia innervate the pineal gland through the nervi conarii (Kappers
1960). Interruption of this regulation pathway by a lesion of the SCN or PVN, or by superior cervical
ganglionectomy abolishes the pineal gland synthesis (Wurtman et al. 1964, Hastings & Herbert 1986,
Bittman et al. 1989). Thus, production of pineal melatonin occurs in response to noradrenergic
stimulation which produces a cascade of biochemical events within the pinealocytes.
The N-acetyltransferase (NAT) activity represents a key regulatory step in melatonin synthesis.
Noradrenaline release from the sympathetic nerves that innervate the pineal gland is normally high at
night and low during the day (Brownstein & Axelrod 1974). In most species, noradrenaline interacts
with both beta1- and alpha1-adrenergic receptors present in the pineal gland (Vanecek et al. 1985). In
the rat pinealocyte, stimulation of adrenergic receptors induces a rise in adenylate cyclase, and the
cyclic adenosine 3 ,´5 -´monophosphate (cAMP) signaling pathway activates the NAT enzyme that
catalyses the rate limiting step of melatonin synthesis (Deguchi & Axelrod 1972, Axelrod 1974,
Sugden 1989). Simultaneous activation of alpha1-receptors potentiates the effects mediated through
the beta1-receptors (Klein et al. 1983). Locally in the pineal gland, the rhythmic melatonin synthesis is
ensured by the oscillating cAMP-dependent transcriptional control mechanism (Stehle et al. 1993,
Foulkes et al. 1996).
Melatonin’s biosynthetical pathway involves tryptophan, one of the 9 essential aminoacids in humans,
as a precursor. Tryptophan is hydroxylated and decarboxylated to serotonin, and then serotonin is
acetylated by the rate-limiting enzyme NAT and further methylated by hydroxyindole-O-
methyltransferase to melatonin (5-methoxy-N-acetyltryptamine) in the pineal gland (Reiter 1991b).
After the synthesis, melatonin is secreted into the blood and cerebrospinal fluid (Smith et al. 1976a,
Smith et al. 1976b, Arendt et al. 1977). Although melatonin is found to be a very lipophilic compound
which readily crosses the blood-brain barrier (Pardridge & Mietus 1980, Le Bars et al. 1991), there is
also evidence of high hydrophilicity of the molecule (Shida et al. 1994).
Irrespective of whether a person is asleep or awake in dim light, melatonin is usually secreted between
2100 and 1000 h, with peak levels occurring between 0200 and 0600 h (Laakso et al. 1990, Laakso et
al. 1994b). The circulating daytime serum levels of melatonin in healthy adults do not normally exceed
20 ng/l, while the range of the nighttime values may be about 20-170 ng/l (Laakso et al. 1990,
Brzezinski 1997).
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In fullterm newborn infants, the rhythm of a melatonin urinary metabolite is not apparent but develops
between the ninth and twelfth week after birth (Kennaway et al. 1992). The highest nocturnal levels
are reached at the age of one to three years (Waldhauser et al. 1993). These peak levels of nighttime
blood melatonin levels and the urinary excretion of melatonin metabolites decrease during puberty
(Waldhauser et al. 1993, Cavallo & Dolan 1996). After the attainment of sexual maturity, there seems
to be a moderate decline of melatonin synthesis until old age (Hartmann et al. 1982, Sack et al. 1986),
although in recent studies the difference in the amplitude of melatonin levels between old and young
subjects was not significant (Luboshitzky et al. 1998, Zeitzer et al. 1999).
Metabolism and pharmacokinetics of melatonin
Melatonin in the circulation is quickly metabolized in the liver primarily to a watersoluble hydroxy
derivative followed by conjugation with sulfate and glucuronic acid (Kopin et al. 1961). The remaining
melatonin is excreted into urine (Lynch et al. 1975, Ozaki & Lynch 1976) or converted into some
other metabolites (Hirata et al. 1974).
Waldhauser and associates (1984) examined the pharmacokinetic profile of exogenously administered
melatonin in healthy humans. After oral administration of melatonin (80 mg) in gelatin capsules during
daytime, the absorption half-life was 0.40 h with an elimination half-life of 0.80 h, and the melatonin
levels ranged between 350 and 10 000 times those occurring endogenously at nighttime. Those
findings are in line with the experiments in which the mean half-time of the elimination phase after oral
administration was 47 min (Di et al. 1997). In both studies a great interindividual variability was
observed in the peak melatonin concentrations. In the study by Di and coworkers (1997) it was
suggested that the variable bioavailability of oral melatonin (intervariability from 10 to 56 %) is a
consequence of variation in hepatic first-pass extraction.
Effects of light on melatonin
Light and dark alterations constitute the principal timing signal of melatonin secretion from the pineal
gland. Light influences melatonin synthesis in three ways in humans. First, light exposure acutely
suppresses elevated melatonin levels. Second, light is able to phase shift the melatonin rhythm. Third,
changes in the photoperiod can alter the melatonin secretion.
Suppressing effects of light
The first piece of evidence for the suppressing effect of light on the enzymatic capacity of the pineal
gland to synthesize melatonin came from the study by Wurtman and coworkers (1963b) in rats. The
early studies in human were unsuccessful in their attempts to suppress melatonin synthesis by light
(Vaughan et al. 1976, Jimerson et al. 1977, Vaughan et al. 1979, Åkerstedt et al. 1979), probably
because neither the exposure conditions nor the light stimulus were optimized.
However, in 1980, Lewy and associates (1980b) showed that also in humans this suppressing effect
takes place if an exposure to bright light occurs during the abundant synthesis of melatonin. The
discovery that bright light (≥2500 lux) could suppress melatonin secretion in humans (Lewy et al.
1980b) led to the assumption that only high-intensity (>500 lux) light is able to affect on human
circadian rhythms. Although human melatonin synthesis is less sensitive to light than that of nocturnal
rodents (Minneman et al. 1974, Illnerová & Vanecek 1979), an interruption or a significant decrease
in the synthesis has been produced by intensities as low as 300 lux (Bojkowski et al. 1987), 350-400
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lux (McIntyre et al. 1989), 500 lux (Laakso et al. 1994c, Hashimoto et al. 1996) or 650 lux (Laakso
et al. 1991). In addition, it has been shown that melatonin is suppressed by light in an intensity- and
duration-dependent manner (Brainard et al. 1988, McIntyre et al. 1989, Aoki et al. 1998).
A study of Brainard and coworkers (1993) suggests that the peak sensitivity for melatonin suppression
is in the blue-green range (509 nm). In fact, in specially controlled conditions when the pupils have
been dilated, the volunteers' heads kept motionless and the light beam directed uniformly on the retina
the mean threshold illuminance of monochromatic light of 509 nm for producing a statistically
significant melatonin suppression is between 6 and 17 lux (photopic) or 28 and 86 lux (scotopic) in
normal volunteers (Brainard et al. 1988); a level of illuminance equal to civil twilight and well below
typical indoor light. This means that under optimal conditions much lower intensities of light can
suppress melatonin than was originally believed.
Phase delaying and advancing effects of light
Studies in humans (Hashimoto et al. 1996) and in golden hamsters (Nelson & Takahashi 1991)
suggest that the threshold intensity of light needed to phase shift the circadian system is greater than
that needed for suppression of the melatonin level. After the suppressing effects of light on human
melatonin secretion (Lewy et al. 1980b) and the theoretical prediction of light PRC (Lewy et al. 1983)
were reported, it was shown that the onset of nocturnal melatonin production could be phase shifted
depending on the timing of the bright light (∼2500 lux) exposure (Lewy et al. 1987). Furthermore, the
PRC to single light pulses of high intensity (∼5000 lux, 3 hours) for human melatonin rhythm was
constructed by Van Cauter and coworkers (1994). This study demonstrated delays or advances of the
melatonin rhythm, indicating that the response to light is phase dependent.
In addition, the magnitude of the phase shifts of melatonin rhythms vary with the number and timing of
light pulses. For example, in a study of Burešová and colleagues (1991), one day after a single
exposure to bright light (∼3000 lux, 6 hours) in the morning, melatonin onset and offset phase
advanced by 0.6-2.6 hours. Dijk and coworkers (1989) reported that an exposure to bright light
during three consecutive mornings (2000 lux, 3 hours) advanced melatonin rhythms by about an hour.
Deacon and Arendt (1994) found melatonin phase delays of about 2-3 hours when exposing the
subjects to light (1200 lux, 6 hours) during three consecutive nights.
Recently, light exposures as weak as the common indoor intensity (150-500 lux) have been shown to
shift the endogenous circadian rhythm of plasma melatonin (Zeitzer et al. 1997, Boivin & Czeisler
1998) and body temperature (Waterhouse et al. 1998) in humans.
Effect of photoperiod
In nonhuman mammals, the photoperiod participates in the regulation of annual rhythms, e.g.
breeding, renewal of fur and body weight rhythms (Martinet & Allain 1985, Zucker et al. 1991).
Humans are not generally considered to be as photoperiodic as other species. A study by Van Dongen
and coworkers (1998) demonstrated the absence of seasonal variation in the phase of circadian
rhythms. However, data from Northern temperate (Beck-Friis et al. 1984, Kivelä et al. 1988) and
Polar regions (Broadway 1987, Makkison & Arendt 1991), and from simulated long and short
photoperiod experiments (Wehr 1991, Burešová et al. 1992, Van Dongen et al. 1997, Vondrašová et
al. 1997) indicate that we retain a number of photoperiodic responses as a function of daylength. For
instance, changes in melatonin levels, in duration of nocturnal melatonin secretion, and in the phase of
the melatonin rhythm have been induced by seasonal variation of natural lighting conditions (Illnerová
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et al. 1985, Martikainen et al. 1985, Kauppila et al. 1987, Kivelä et al. 1988, Laakso et al. 1994b,
Stokkan & Reiter 1994, Luboshitzky et al. 1998). These findings suggest that the regulation of
melatonin is influenced by the photoperiod in humans as in other mammals.
Melatonin as a circadian effector
Melatonin is evolutionarily well preserved and present in most organisms, from unicell algae to
humans (Pelham et al. 1973, Smith et al. 1976a, Hardeland & Fuhrberg 1996). Melatonin’s role as a
phylogenetically conservative signal might be associated with its involvement in the adaptation of early
living cells to the demands of climate. According to a hypothesis of Paietta (1982), the increased level
of free oxygen in the early eukaryote evolution could have pushed the organisms to minimize the
deleterious effects of the diurnal photooxidative exposures by developing circadian rhythmicity of
metabolic activities. In addition, melatonin can detoxify highly reactive oxygen radicals (Poeggeler et
al. 1993, Reiter et al. 1993, Tan et al. 1993). Therefore, melatonin as a natural oxidant may represent
a property which during evolution has made this molecule a suitable indicator of the dark period
(Hardeland 1993).
The effects of pinealectomy and melatonin administration on rhythms in animals
Pinealectomy, in which the lack of clear rhythmical production of melatonin is induced surgically,
results in the elimination of the normal circadian rhythm of locomotor activity in birds (Gaston and
Menaker 1968), whereas in rats pinealectomy has little effect on free-running circadian activity
patterns (Richter 1964, Richter 1967, Quay 1968, Karppanen et al. 1973). However, pinealectomized
rats do re-entrain to the phase-shifted photoperiods more rapidly than their sham-operated controls
(Quay 1970).
A major step was taken in the studies of the role of melatonin in mammalian circadian organization in
1983 when Redman, Armstrong and Ng (1983) reported that daily injections of melatonin entrained
the circadian locomotor rhythms of rats in constant dim red light. Somewhat later, it was shown that
exogenous melatonin was able to phase shift activity rhythms (Redman & Armstrong 1988). In
constant light, however, melatonin injections are not always able to repair a light-induced disruption of
the rhythms (e.g. wheel-running or locomotor activity, drinking, and body temperature), while a clear
synchronization occurs in some individuals (Chesworth et al. 1987, Thomas & Armstrong 1988,
Marumoto et al. 1996, Deprés-Brummer et al. 1998, Witte et al. 1998). Thus, the mammalian pineal
seems not to be essential for the generation of the circadian rhythm of locomotor activity, and the
action of melatonin as a circadian synchronizer may be somewhat limited in strength (reviewed by
Redman 1997).
The relationship between intrinsic rhythms and external signals is classically defined by phase response
curves. The first PRC to melatonin in a vertebrate was conducted by Underwood (1986). Exogenous
melatonin injected into free-running lizards induced phase delays (injections were administered late in
the subjective night or in the first half of the subjective day) or phase advances (injections were
administered between midsubjective day or early subjective night) of circadian activity rhythms.
Afterwards, the PRC to melatonin was also constructed in other animals, e.g. in rats (Armstrong
1989). 
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The effects of exogenous melatonin on rhythms in humans
The first finding on a substance which had melanin aggregating and chromatographic properties
similar to those of melatonin and a cyclic pattern was published in 1973 by Pelham and coworkers
(1973) in humans. After that study, several studies have yielded evidence about melatonin’s role as a
rhythm modulator. For example, Arendt and colleagues (1985) first suggested that exogenous
melatonin administration might be able to phase advance the endogenous melatonin profile. After it
had been shown that daily melatonin administration induced a phase advance of the endogenous
melatonin rhythm in blind subjects (Sack et al. 1991), Lewy and coworkers (1992) provided the first
piece of evidence for a human PRC to melatonin (Figure 1). Melatonin administration in the morning
elicited phase delays, and administration in the afternoon or early evening induced phase advances of
the endogenous melatonin onset. In addition to the phase shifting effects of exogenous melatonin,
Sack and associates (1991) have demonstrated a normally entrained endogenous melatonin rhythm in
one blind person after about a year of melatonin treatment.
Compared to the human phase-response curve to light (Minors et al. 1991), PRC to exogenous
melatonin (Lewy et al. 1992, Zaidan et al. 1994, Lewy et al. 1998a) has been described to be nearly
opposite in phase (Fugure 1). In practice, the optimal time to produce a phase delay by exogenous
melatonin is near the offset of endogenous secretion (at about 0700 h) and the optimal time of day to
administer melatonin to produce a phase advance is 4-8 h before the onset of endogenous melatonin
(at about 1700 for people on a conventional schedule) (Lewy & Sack 1997, Lewy et al. 1998a). Other
circadian hormonal rhythms (e.g. cortisol, prolactin) and temperature rhythms can also be affected by
melatonin administration (Arendt et al. 1987, Mallo et al. 1988, Kräuchi et al. 1997b).
Melatonin binding sites and feedback to the pacemaker
Although an intracellular function and a direct gene regulatory action of melatonin have been
suggested (Carlberg & Wiesenberg 1995, Steinhilber & Carlberg 1999), many of the established
effects of physiological concentrations of melatonin have been shown to be mediated via high-affinity
cell membrane receptors belonging to the superfamily of G-protein-coupled receptors (reviewed by
Kokkola & Laitinen 1998).
Based on sequence dissimilarities, melatonin receptors are classified into three subtypes (Mel1a, Mel1b
and Mel1c), and two of the subtypes (Mel1a and Mel1b) have been found in mammals (Kokkola &
Laitinen 1998). The regions which show specific melatonin-binding in most mammals studied are the
SCN and the hypophyseal pars tuberalis (Morgan et al. 1994). In humans, melatonin-binding sites are
found in various regions of the brain, including the SCN (Weaver et al. 1993, Weaver & Reppert
1996), the temporal cortex (Fauteck et al. 1995), the cerebellum (Fauteck et al. 1994) and possibly in
the hypophyseal pars tuberalis (Weaver et al. 1993), and also in peripheral sites such as the kidney
(Song et al. 1995), granulosa cells (Yie et al. 1995) and prostate (Laudon et al. 1996).
There is also evidence of circadian oscillators within the SCN which are sensitive to the pineal
hormone melatonin, raising the possibility that the circadian organization may be modulated by pineal
feedback via melatonin. First, specific melatonin receptors in the SCN (Vanecek et al. 1987, Reppert
et al. 1988, Morgan et al. 1994), also in humans (Weaver et al. 1993), provide a critical link for a
functional feedback loop whereby circulating melatonin can influence the circadian pacemaker.
Second, pinealectomy, i.e. suppressed melatonin production, increases the density of these binding
sites (Gauer et al. 1992), and can alter the firing-rate rhythm in the SCN (Rusak & Yu 1993).
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Third, the pinealectomy-induced increase in the density of binding sites can be inversed by a single
melatonin injection (Gauer et al. 1993). In addition, exogenous melatonin inhibits the spontaneous
electrical activity of the SCN of the rat when melatonin is administered near the transition to subjective
night (Mason & Brooks 1988, Shibata et al. 1989, Stehle et al. 1989). In fact, the circadian rhythm of
the discharge rate of the SCN can be reset by melatonin within two windows of sensitivity
corresponding to dusk and dawn (McArthur et al. 1991, McArthur et al. 1997).
Fourth, melatonin alters the metabolic activity of the rat SCN (Cassone et al. 1988). Administration of
melatonin to rats induced expression of Fos, the protein product of the c-fos proto-oncogene, in the
SCN (Kilduff et al. 1992), and in vivo a single melatonin administration phase advanced the evening
rise in the light-induced SCN c-fos expression (Sumová & Illnerová 1996). In conclusion, it seems that
melatonin may modulate circadian overt rhythms probably by coupling individual oscillators to form an
internal synchronization and affecting the photic sensitivity of the circadian timing system.
Other effects of melatonin
Biological calendar of reproduction
Previous classical studies on melatonin have mainly focused on its action on the hypothalamic-
hypophyseal-gonadal axis, whereby it controls seasonal reproduction (Reiter 1980, Tamarkin et al.
1985). Because melatonin can act as a signal of photoperiod to the body, a long duration of melatonin
secretion at night may cause gonadal atrophy in spring and summer breeders (e.g. hamsters), and
gonadal growth in species which breed in the autumn and winter (e.g. sheep) (Bartness et al. 1993). In
addition, melatonin was found to have antigonadal effects on rodent species that are not seasonal
breeders (e.g. rats, mice) (Wurtman et al. 1963a, Glass & Lynch 1981).
In the late 19th century, Otto Heubner (1898) observed precocious puberty in a child with a pineal
tumour. Since then, there have been several reports about the relationship between sexual maturation
disorders and abnormal melatonin levels (Berga et al. 1988, Karasek et al. 1990, Puig-Domingo et al.
1992, Luboshitzky et al. 1995). Although correlations between melatonin and reproductive hormones
have been observed in humans, the functional relationship remains to be determined (reviewed by
Luboshitzky & Lavie 1999).
Melatonin as a protective agent
Melatonin has been found to be a potent intracellular scavenger of hydroxyl and peroxyl free radicals
when administered at pharmacological doses both in vivo and vitro (Reiter 1995, Reiter 1998),
suggesting that it has a protective role against oxidative damage. For instance, melatonin treatment
may be beneficial in some neurodegenerative diseases, e.g. Alzheimer's and Parkinson's diseases
(Reiter 1998, Reiter et al. 1998).
Melatonin may also function as an immunomodulator, and the immunoenhancing action seems to be
mediated by certain T-lymphocytes and lymphokines (Maestroni 1993, Neri et al. 1998). In addition,
some antitumoral effects of melatonin have also been reported (Buswell 1975, Wilson et al. 1992,
Lissoni et al. 1995, Lissoni et al. 1996). In contrast to these findings, melatonin has been shown to be
able to promote melanoma growth in hamsters (Stanberry et al. 1983) and induce suppression of
human lymphocyte natural killer cell activity in vitro (Lewinski et al. 1989).
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Furthermore, it has been suggested that melatonin has a role in the modulation of brain
excitability. An anticonvulsant potential of exogenous melatonin has been proposed on the basis
of in vivo studies in humans (Anton-Tay 1974, Brueske et al. 1981, Molina-Carballo et al. 1997,
Jan et al. 1999) and an in vitro experiment in which epileptiform activity in human temporal slices
was reduced by melatonin (Fauteck et al. 1995). On the other hand, Sheldon (1998) reported that
melatonin induced an increased seizure frequency in 4 of 6 neurological patients. Taken together,
it seems that the effects of melatonin may not be completely protective.
Extrapineal melatonin
The pineal gland is not the only source of melatonin hormone. The suggestion that extrapineal
melatonin exists in humans was made by Raikhlin and coworkers (1975) when they blanched the
frog’s skin with extracts of human intestinal mucosa. In fact, the gastrointestinal tract represents the
most abundant extrapineal source of melatonin, for it contains over 80 times more melatonin than the
pineals of chicks and rats (Huether et al. 1992). Arrhythmic melatonin levels have been observed in
alligators (Alligator mississippiensis) lacking pineal bodies (Roth et al. 1980). Melatonin is also found
in the blood of surgically pinealectomized rats (Ozaki & Lynch 1976, Pang et al. 1977). In vertebrate
retinas, melatonin is thought to act locally to regulate various dark-adaptive functions (Cahill &
Besharse 1995). Melatonin is also synthesized in small amounts in the human retina (Leino 1984), but
the role of extrapineal melatonin in circadian functions in humans is not known.
BLINDNESS AND CIRCADIAN RHYTHMS
The entry of the amount of light needed for the resetting of the rhythms to the circadian timing system
may be prevented by blindness. Thus, blind people may fail to maintain the circadian rhythms of sleep
and wake, body temperature, melatonin and cortisol synchronized with the LD cycles (Miles et al.
1977, Orth et al. 1979, Smith et al. 1981, Lewy & Newsome 1983, Okawa et al. 1987, Nakagawa et
al. 1992, Sack et al. 1992b, Klein et al. 1993, Palm et al. 1997, Klerman et al. 1998, Skene et al.
1999, Lockley et al. 2000). They may have sleep-wake disruption and may develop either free-running
circadian rhythms or disorganized sleep-wake cycles (Arendt et al. 1988, Lockley et al. 1997a,
Lockley et al. 1997b, Tabandeh et al. 1998, Lockley et al. 1999). In addition, periodic insomnia and
daytime sleepiness (Sack et al. 1992b, Tzischinsky et al. 1992) may occur when the internal clock
becomes desynchronized from the solar and social 24-hour cycle.
Although in a study by Czeisler and coworkers (1995), a 3-hour, 10000-lux facial light exposure in
patients with different origins of blindness (e.g. retinopathy or optic neuropathy) did not suppress
melatonin synthesis in most of the 11 blind subjects with no conscious perception of light, a clear
decrease of melatonin was found in 3 subjects who had totally lost the pupillary reflexes. The light
suppressing effect was only found when the patients' eyes were uncovered. This work indicates that in
a subgroup of patients without conscious light perception the photic pathway through the eyes used by
the circadian system may be functional.
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Patients with neuronal ceroid lipofuscinosis and blindness
Classification of NCL diseases
Neuronal ceroid lipofuscinoses (NCLs) are the most common group of progressive neurodegenerative
diseases of childhood in the Western world. The disorders were first described by Stengel, Batten and
others in the 19th and early 20th centuries (reviewed by Goebel et al. 1999), and termed neuronal
ceroid lipofuscinoses by Zeman and Dyken (1969) because the neural and extraneural accumulation of
storage material resembled ceroid and lipofuscin. Based on recent findings on molecular genetics,
NCLs can be classified as atypical lysosomal storage diseases (Mole 1998, Mole et al. 1999).
Classically, NCLs have been devided into four main forms: the infantile (INCL, Santavuori-Haltia
disease), late infantile (LINCL, Jansky-Bielschowsky or early onset Batten disease), juvenile NCL
(JNCL, Spielmeyer-Vogt-Sjögren or late onset Batten disease) and adult onset NCL (Kufs’ disease
and Parry disease). In addition, a congenital NCL and Northern Epilepsy Syndrome (Progressive
Epilepsy with Mental Retardation) have been reported (Hirvasniemi et al. 1994, Goebel et al. 1999).
To date, depending on the age of onset, clinical course of the disease, characterization of the
storage material, presence of vacuolated lymphocytes, and chromosomal location of the disease
gene, at least 11 childhood and two adult types are recognized (Mole 1999). All childhood and
most adult types are inherited in an autosomal recessive fashion. According to present
knowledge, eight genes (symbols from CLN1 to CLN8) underlie NCLs (Goebel et al. 1999). Five
of the genes have been identified: CLN1 (INCL), CLN2 (classical LINCL), CLN3 (JNCL), CLN5
(Finnish variant LINCL) and CLN8 (Northern Epilepsy Syndrome) (Vesa et al. 1995, Sleat et al.
1997, The International Batten Disease Consortium 1995, Savukoski et al. 1998 and Ranta et al.
1999, respectively). In addition, 86 different disease-causing mutations have been reported
(http://www.ucl.ac.uk/ncl, accessed on Mar 23, 2000).
Incidence and common symptoms of NCL diseases in Finland
The most common NCL types in Finland are INCL and JNCL, whereas LINCL is rarer (Santavuori
1999). One adult form of NCL has been diagnosed in Finland (Haltia, personal communication). At
present, the incidence of INCL is 1:20000, approximating three new INCL patients per year
(Santavuori 1999, Santavuori personal communication). Altogether 158 INCL patients have been
diagnosed. The number of diagnosed LINCL patients is 31, consisting of five classic LINCL (gene
symbol CLN2) and 26 variant LINCL (CLN5) patients. 185 JNCL patients have been diagnosed, with
an incidence of 1:21000.
NCL children are healthy at birth with normal development until the onset of the disease. In the most
common Finnish NCL types, including INCL (gene symbol CLN1) and JNCL (CLN3), the clinical
course is characterized by loss of vision, epilepsy, progressive cognitive impairment, and psychomotor
disturbances leading to premature death.
Clinical picture of INCL
In INCL patients the development is normal until the age of 0.5-1 year, and in some children until 1.5
years (Santavuori 1988). The onset of epilepsy occurs at the mean age of 30 months (Vanhanen
1996). INCL patients suffer from anxiety and hyperexcitability (Santavuori 1988) causing sleep
problems, which are among the most disturbing factors in the everyday life of the patients and their
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families. In our earlier study a fragmented activity rhythm was observed in 4 of 5 INCL patients, but
disturbances in the daily melatonin and cortisol rhythms occurred only in the minority of patients, and
only at an advanced stage of the disease (Heikkilä et al. 1995).
In neurophysiological examination of INCL patients, electroencephalogram (EEG) shows
posterior low activity to eye opening and closing starting at a mean age of 1.8 (range 1.4-2.3)
years, and the activity in the EEG disappears after the age of 2.7 years (Vanhanen et al. 1997).
Neuroradiological findings by magnetic resonance imaging (MRI) may show hypointensity of the
thalamus as compared with the white matter and basal ganglia, and cerebral and cerebellar
atrophy (Autti et al. 1997,Vanhanen et al. 1994).
The condition of the patient deteriorates rapidly and before the age of 3 years the child has lost all
cognitive and active motor skills (Santavuori et al. 1974). Death usually takes place at the age of 8-13
years (Santavuori et al. 1999).
The characteristic neuropathological finding in INCL patients is extreme atrophy of the brain, whereas
the brain stem and particularly the spinal cord are less affected (Haltia et al. 1973, Santavuori et al.
1974). The consistency of the brain is tough and rubberlike, and all cerebral gyri are narrowed and
sulci widened (Haltia et al. 1973).
Pathology of visual system in INCL
Blindness is one of the main symptoms in INCL patients, and visual disturbance is usually observed
between 12 and 24 months of age (Santavuori et al. 1974). Perception of light can be lost as early as
at the age of 18 months, but most often a few months later (Kohlschütter & Goebel 1997). Visual
failure leads rapidly to blindness. INCL children are usually practically blind at the age of two (Raitta
& Santavuori 1973). Pupillary reactions are slow or absent after the age of two years (Santavuori et
al. 1974) but, surprisingly, may reestablish during a later stage of the disease (Santavuori et al. 1999).
The earliest ophthalmoscopical findings are hypopigmentation of the fundus without distinct macular
changes (Raitta & Santavuori 1981). Macular changes appear by the age of 12-18 months as
depigmentation and mottling of the pigmentlayer. In fluoresceinangiography the changes can be
distinguished by the age of 18-24 months and are parallel to the general dystrophy of the retina.
Retinal vessels become extremely narrow. They are hardly visible by the age of 3 years when the optic
disc appears atrophic (Raitta & Santavuori 1981). In addition to retinal degeneration, clearly visible
choroidal vessels are seen (Santavuori et al. 1974). Pigment aggregation of the fundus periphery is not
usually found in INCL patients (Raitta & Santavuori 1973, Kohlschütter & Goebel 1997).
In neurophysiological examination, visual evoked potential (VEP) and electroretinogram (ERG)
abnormalities appear between 22 and 25 months of age (Vanhanen et al. 1997). The mean age of
abolition of ERG is 3.1 (range 2.3-4.1) years and that of VEP 3.8 (2.2-5.4) years.
Neuropathological autopsy of 5 INCL patients showed that the retinas were completely destructed
(Tarkkanen et al. 1977). The retina was severely atrophic with complete loss of photoreceptors,
bipolar and ganglion cells which were replaced by marked glial proliferation. Loss of pigment in the
retinal pigment epithelium had taken place to some extent. The optic nerve was atrophic and gliosed
with a complete loss of myelin sheets. In addition, there was accumulation of granular material in the
nonpigmented ciliary epithelium, the retina, the retinal pigment epithelium, and the optic nerve.
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Clinical picture of JNCL
In JNCL patients the disease usually becomes manifest at early school age. The first symptom is
usually visual failure detected between 4 and 7 years of age (Santavuori 1988). At first, mental
impairment is slight and apparent only in school performance.
Some time after the onset of visual loss, a personality change may be noted which can be accompanied
by various types of psychiatric disturbances (Boustany 1992, Wisniewski et al. 1992, Hofman et al.
1999). The greatest decline in motor functions and intelligence usually takes place between 11 and 15
years of age (Järvelä et al. 1997). The onset of epilepsy occurs, on the average, at the age of 11 years
(Järvelä et al. 1997).
Sleep problems are reported in more than half of JNCL patients (Santavuori et al. 1993). The most
common problems include frequent awakenings, difficulties in falling asleep, nightmares and night
terrors. Despite the disturbances observed in the sleep-wake rhythm in 7 of 8 JNCL patients, most of
the patients had normal melatonin, cortisol and temperature rhythms (Heikkilä et al. 1995).
In neurophysiological recordings, EEG is usually found normal at the preclinical stage, and normal or
slightly abnormal by the age of 5-6 years in most patients (Santavuori et al. 1988). In MRI, abnormal
periventricular white matter may be found in all age groups, and the thalamus, caudate nucleus and
putamen usually give low signal in patients above the age of ten years (Autti et al. 1996). During the
progression of the disease, movement difficulties develop (Boustany 1992, Wisniewski et al. 1992,
Hofman et al. 1999). The disease leads to death at the mean age of 24 years (Järvelä et al. 1997).
In neuropathological examination of JNCL patients, the macroscopic appearance of the brain may
be nearby normal (Zeman & Dyken 1969, Zeman et al. 1970). The cerebral cortex is slightly
atrophic,  whereas  the  number  of  neurons  is  usually  not  markedly  reduced.  The  most  marked
changes in the white matter are seen in periventricular areas (Vanhanen et al. 1995).
Pathology of the visual system in JNCL
In JNCL patients the leading initial symptom is visual failure. The visual problems are noticed at a
mean age of 5.8 (range 4-10) years, and the patients become practically blind between 6 and 20 years
of age (Järvelä et al. 1997, Kohlschütter & Goebel 1997). The characteristic ophthalmological findings
are retinal degeneration, macular dystrophy, optic atrophy and thinning of vessels (Spalton et al. 1980,
Traboulsi et al. 1987, Santavuori 1988, Seeliger et al. 1997, Neppert & Kemper 1998). In addition,
the typical pigment aggregation is usually seen in the peripheral retina (Raitta & Santavuori 1981,
Kohlschütter & Goebel 1997).
In neurophysiological examination, ERG is usually abolished around 6 years of age (Santavuori et al.
1988, Kohlschütter & Goebel 1997, Seeliger et al. 1997, Weleber 1998). VEP is pathological when
clinical signs are apparent and usually become abolished between 13 and 16 years. In some patients
VEP was still recordable, although abnormal, between the age of 18 and 21 years (Santavuori et al.
1988). The abnormality of the ERG is usually seen as a severe loss of rod and cone responses
(Horiguchi & Miyake 1992, Seeliger et al. 1997, Weleber 1998).
Pathological examination of one JNCL patient revealed a near-complete loss of photoreceptors
(Traboulsi et al. 1987). The autopsy of 3 JNCL patients showed that two of them had lost all retinal
photoreceptor cells, whereas in one patient with the shortest clinical course of the disease there were
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still photoreceptors present in the periphery of the retina (Goebel et al. 1974). Changes were observed
in the optic nerves, ganglion cell layers and the pigment epithelium (Goebel et al. 1974, Traboulsi et
al. 1987) but the choroid and sclera were normal (Traboulsi et al. 1987).
Treatment of NCL diseases
At present, the treatment of NCLs is merely palliative, including medication (e.g. antiepileptics and
antiparkinsonian drugs, analgetics, antidepressants, antipsychotic therapy, antioxidants and hormonal
treatment) combined with family guidance, psychological support, social help, artificial feeding,
physiotherapy, speech and occupational therapy (Hofman et al. 1999, Santavuori et al. 1999). Thus,
there is no cure yet for this devastating group of diseases. However, new forms of treatment will
hopefully emerge as the understanding of the pathological processes increases.
PRACTICAL CONSIDERATIONS OF LIGHT AND MELATONIN
The current knowledge about the effects of light and melatonin on human physiology is partly based
on unsystematic observations. The indications for phototherapy and melatonin administration are not
yet conclusively established, neither are the long-term benefits and risks thoroughly known.
Patients treated with bright light have reported some temporary side effects including headache,
eyestrain, irritability, nausea and insomnia (Levitt et al. 1993). There is also evidence that symptoms of
mania may emerge as a consequence of phototherapy (Schwitzer et al. 1990). However, short- or
long-term daily treatment with 10 000 lux light has not been observed to result in ocular changes in
patients suffering from seasonal affective disorder (Gallin et al. 1995).
Melatonin is available as a nutritional supplement in the US without a premarket approval from the
FDA (Food and Drug Administration), and it is widely sold in health-food and drug stores. In Canada,
Finland, Great Britain and some other European countries melatonin is classified as a medicine and
available only on prescription. However, the standard clinical trial methodologies for judging the safety
of a drug have not been applied to melatonin. Indeed, very little is known about the long-term adverse
effects of melatonin in humans. The results of experiments in rodents indicate low toxicity (Sudgen
1983, Jahnke et al. 1999) and no mutagenicity (Neville et al. 1989). This is consistent with the human
studies in which doses ranging from 0.1 mg to several grams have not been found to result in medical
catastrophes (Lerner & Nordlund 1978, Wirtz-Justice & Armstrong 1996, Sack et al. 1997, Zhdanova
et al. 1997).
The potential side effects of melatonin are drowsiness (Arendt et al. 1984, Dollins et al. 1993, Dollins
et al. 1994) and phase shifting of circadian rhythms (Dawson & Armstrong 1996). In addition, sleep
could be disrupted if melatonin is not properly timed (Middleton et al. 1996b). The possible adverse
effects of melatonin also include cutaneous flushing, gastrointestinal disorders, headache and vascular
constriction (Papavasiliou et al. 1972, Guardiola-Lemaître 1997, Mahle et al. 1997).
The most common group of diseases or symptoms treated with light or exogenous melatonin
comprises circadian disorders, which are linked to poor resetting of the circadian timing system and
usually associated with free-running or abnormal overt rhythms. Disturbances in the circadian control
of various body functions have been found to be related to working during unusual hours (Sack et al.
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1992a, Weibel et al. 1997) and jet lag (Désir et al. 1981, Fevre-Montange et al. 1981, Désir et al.
1982, Goldstein et al. 1983, Härmä et al. 1993, Suvanto et al. 1993). In addition, abnormal circadian
rhythms have been suggested to underly the sleep difficulties of blind people (Arendt et al. 1988,
Nakagawa et al. 1992, Lockley et al. 1997a, Lockley et al. 1997b, Tabandeh et al. 1998, Lockley et
al. 1999), of some neurologically disabled children (Laakso et al. 1993, Palm et al. 1997, McArthur &
Budden 1998, O'Callaghan et al. 1999, Zhdanova et al. 1999) and of the elderly (Haimov et al. 1994).
Circadian pathology has been suggested to be related to some affective disorders (Wehr & Goodwin
1983).
Circadian rhythm sleep disorders
The sleep-wake cycle is one of the most obvious rhythms regulated by the circadian clock. The
disorders that are related to the timing of sleep within the 24-hour day are named circadian rhythm
sleep disorders (American Sleep Disorders Association 1997). In most of the disorders, the underlying
problem is that the person cannot sleep or be awake when desired, needed, or expected.
The phase shifts of circadian rhythms are the probable mechanism by which light improves sleep (Dijk
et al. 1995). The alerting and activating property of bright light exposures has also been proposed to
be one possible way in which light affects arousal and sleep onset (Campbell et al. 1995).
Administration of melatonin might improve sleep by producing corrective circadian phase shifts
(Zhdanova et al. 1997), thereby improving the alignment of the endogenous sleep propensity rhythm
with the desired sleep schedule (Sack & Lewy 1997). In addition, melatonin may increase sleepiness
by a soporific effect (Wirz-Justice & Armstrong 1996).
After rapid air travel across several time zones, the endogenous circadian timing system is
desynchronized and begins to adapt to new environmental time cues (American Sleep Disorders
Association 1997). Because the adjustment process of the circadian system is slow, jet lag symptoms,
e.g. disturbed sleep, daytime sleepiness and impaired performance, can last for several days after the
flight. Scheduled exposure to bright light can alleviate the symptoms (Daan & Lewy 1984, Boulos et
al. 1995). During the lasts ten years, evidence has accumulated about the ability of melatonin
administration to decrease jet lag symptoms (Arendt & Marks 1983, Arendt et al. 1986, Arendt et al.
1987, Petrie et al. 1989, Claustrat et al. 1992, Petrie et al. 1993), although in a recent extensive study
by Spitzer and coworkers (1999) melatonin did not show any beneficial effects as compared with
placebo.
Shift work is a common cause of circadian rhythm sleep disorders. The symptoms, e.g. difficulties in
sleep maintaining and reduced alertness and performance, can be explained by a mismatch between the
work-sleep schedule and the internal circadian rhythms (American Sleep Disorders Association 1997).
There is evidence indicating that maladaptation to shift work can be treated with properly timed
exposures to light (Dawson & Campbell 1991, Bjorvatn et al. 1999). Also, the use of artificial
nocturnal bright light combined with enforced daytime dark periods can phase shift circadian rhythms
effectively despite  an exposure to conflicting  24-hour time cues  (Czeisler et al. 1990,  Eastman  et al.
1994,  Koller  et  al. 1994,  Eastman  & Martin 1999). Application of  exogenous melatonin has been
tested as therapy in sleep disorders of night workers (Folkard et al. 1993).
The delayed sleep phase syndrome is a disorder in which the major sleep episode is delayed in relation
to the desired clock time, resulting in symptoms of sleep-onset insomnia or difficulty in awakening at a
desired time (American Sleep Disorders Association 1997). Unlike the advanced sleep phase
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syndrome, which is rather rare, the delayed sleep phase syndrome is quite a common sleep schedule
disorder. Lewy and coworkers (1985) were the first ones to recommend the use of a morning light
exposure to treat the delayed sleep phase syndrome. After that study, more evidence has been
obtained about the beneficial implications of light (Rosenthal et al. 1990) and melatonin (Dahlitz et al.
1991, Tzischinsky et al. 1993, Oldani et al. 1994, Dagan et al. 1998) in the therapy of the delayed
sleep phase syndrome.
Blind people may have a non-24-hour sleep cycle that reflects a nonentrained intrinsic rhythm of the
circadian pacemaker (American Sleep Disorders Association 1997), resulting in recurrent insomnia
and daytime sleepiness (Sack et al. 1992b, Tabandeh et al. 1998). Several reports indicate beneficial
effects of melatonin administration in these patients (Arendt et al. 1988, Folkard et al. 1990,
Sarrafzadeh et al. 1990, Sack et al. 1991, Tzischinsky et al. 1992, Lockley et al. 2000).
Melatonin has also been found to promote sleep in patients with neurological disabilities, especially in
those with circadian sleep disorders (Palm et al. 1991, Jan et al. 1994, Lapierre & Dumont 1995, Palm
et al. 1997, McArthur & Budden 1998, O'Callaghan et al. 1999, Zhdanova et al. 1999). On the other
hand, controversial effects have also been observed in children with mental retardation and fragmented
sleep (Camfield et al. 1996), and melatonin was also ineffective in our previous study in neuronal
ceroid lipofuscinosis patients with fragmented or normal motor activity rhythms (Hätönen et al. 1999).
In addition, bright light therapy has been demonstrated to have some positive effects in neurologically
disabled children with sleep-wake rhythm problems (Guilleminault et al. 1993).
The study of Haimov and associates (1994) has documented lower melatonin levels in elderly people
with poor sleep compared with the elderly with no sleep complaints. It is suggested that exogenously
administered melatonin may be beneficial in elderly insomniacs (Garfinkel et al. 1995, Haimov et al.
1995), and in sleep problems that are related to melatonin deficiency (Etzioni et al. 1996, Lehmann et
al. 1996). On the other hand, a study of Youngstedt and coworkers (1998) showed no association
between low melatonin and insomnia. Furthermore, bright light treatment has been shown to have
beneficial effects on rest-activity rhythm disturbances and sleep maintaining in old demented patients
and elderly subjects (Murphy & Campbell 1996, Van Someren et al. 1997).
Seasonal affective disorder
Seasonal affective disorder (SAD) was originally defined as a syndrome in which depression
developed during the autumn or winter and remitted in the spring or summer (Marx 1946, Rosenthal
et al. 1984). At present, it is classified as a form of recurrent depressive or bipolar disorder, and it is
characterized by episodes that vary in severity (Partonen & Lönnqvist 1998).
Bright light exposure treatment has been used successfully in SAD (Lewy et al. 1987, Eastman et al.
1992, Partonen 1994, Eastman et al. 1998, Lewy et al. 1998c, Terman et al. 1998). However, the
mechanism by which light reduces depressive symptoms is unknown, and even nonphotic high-density
negative air ionization has been shown to act as an antidepressant in patients with SAD (Terman et al.
1998). This rhythmic blue disorder was also proposed to be linked to melatonin secretion (Lewy et al.
1987), but later findings showed that winter depression patients do not have abnormal melatonin levels
(Checkley et al. 1993), and melatonin suppression does not appear to be causally involved in the
antidepressant effects of bright light therapy on the affective illness (Dietzel et al. 1985, Wehr et al.
1986). Exogenous melatonin has been demonstrated to decrease (Lewy et al. 1998b) or have no effect
on (Witz-Justice et al. 1990) the depressive symptoms of SAD patients. However, because alternative
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treatment is available for SAD, such as nondrug therapy by bright light, melatonin is not considered a
first-choice treatment at the present time.
Conclusions of light and melatonin treatment
Light may well affect mood (Lewy et al. 1987, Eastman et al. 1992, Partonen 1994, Eastman et al.
1998, Lewy et al. 1998c, Terman et al. 1998). In fact, there is now general agreement that the
treatment of choice in patients suffering from seasonal affective disorder is bright light exposures
(Partonen & Lönnqvist 1998). In addition, light therapy can be useful in the treatment of delayed and
advanced sleep phase syndromes (Chesson et al. 1999). However, the benefits of light treatment are
less clear in jet lag, shift work, and in non-24-hour sleep-wake syndrome of blind people. Above all,
further applied research in everyday conditions is required, because it is important to find out how
alterations in indoor and outdoor lighting conditions and avoidance of bright light exposures affect the
entrainment of circadian timing system.
Although melatonin promotes sleep in humans (Zhdanova et al. 1997), it is clear that melatonin is not
primarily a sleep hormone, because in nocturnal species melatonin is associated with wake and activity
(Mendelson et al. 1980, Huber et al. 1998). The majority of published data indicates that melatonin
has a therapeutic potential in circadian rhythm-related sleep disorders (Arendt et al. 1997, Arendt &
Deacon 1997). As yet, however, its mechanism of action remains unclear, the appropriate dose, timing
and method of delivery with respect to any given condition and individual are uncertain, the
contraindications remain to be defined, and there are virtually no data on the long-term safety or about
the use with concomitant medication or organic disease.
Although melatonin functions in mammalian physiology as an important photoperiodic messenger
molecule (Wehr 1997), very little information is available concerning its function as a neuroendocrine
phototransducer in humans. Indeed, much further research is needed on melatonin's interaction with
light and LD alterations.
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AIMS OF THE STUDY
This thesis was focused to examine the significance of light in the regulation of human melatonin
hormone.
The results of the investigations performed before the present studies give rise to the following
conclusions. Blindness may prevent the entry of light to the circadian system and the circadian
rhythms are free-running in many blind people. In our earlier study, however, it was found that
the cortisol and melatonin rhythms in blind neuronal ceroid lipofuscinosis patients were disturbed
only in a minority of the patients. The transduction of light declines also in sighted people when
the eyes are closed, but there was no former evidence of light-induced reduction of melatonin
levels through closed eyelids. Further, it was thought that shifting the phase of the melatonin
rhythm requires higher illuminances than the suppression of melatonin levels. There was no
earlier information about the phase shifting effect of low intensity light in humans. Furthermore,
light acutely suppresses melatonin levels during the abundant melatonin synthesis and both light
and melatonin are able to reset the circadian timing system, suggesting that the direct suppressing
effect of light on the secretion of melatonin can be one of the factors related to the phase shifting
of the melatonin rhythm.
Based on prior knowledge we formulated four hypotheses presented below. Light-induced
changes in the secretion of melatonin were investigated to gain the following specific objectives.
I) Light suppresses melatonin synthesis in blind neuronal ceroid lipofuscinosis patients.
The ability of bright light to suppress melatonin synthesis in blind neuronal ceroid lipofuscinosis
patients with degenerated retinas was investigated in order to find out whether an intact retina is
needed for the transmission of light to the human circadian timing system.
II) Closed eyelids limit the entry of photic information to the hypothalamic level.
The ability of bright light to suppress melatonin synthesis through closed eyelids in healthy people was
investigated in order to find out how much closed eyelids (e.g. during sleep) limit the transmission of
light to the circadian timing system.
III) Moderate illuminance induces a phase delay of the human melatonin rhythm.
The ability of ordinary room illuminance to induce a phase shift of the melatonin rhythm in healthy
people was investigated in order to find out whether the melatonin rhythm of urbanized people is
adjusted by light in everyday conditions.
IV) Exogenous melatonin counteracts the light-induced phase delay of the melatonin rhythm.
The ability of exogenous melatonin to nullify the phase shifts of the endogenous melatonin rhythm
induced by bright light was investigated in order to find out whether the effect of light on the human
melatonin rhythm is mediated by a mechanism involving a decrease of melatonin concentration.
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MATERIALS AND METHODS
More detailed descriptions of the materials and methods are presented in the original publications.
ETHICAL CONSIDERATIONS
All volunteers (II,III,IV), the control subjects (I), one patient and the relatives of the mentally retarded
patients (I) gave written informed consent after the nature of the experiments had been explained
(Declaration of Helsinki). The study plans (I,IV) were approved by the Ethical Committees of the
Institutions. The oral administration of melatonin (IV) was permitted by the Finnish National Agency
for Medicines, Ministry of Social Affairs and Health.
SUBJECTS AND GENERAL PROCEDURES
Suppression of melatonin without conscious light perception
The penetration of light information to the hypothalamic level and pineal gland of clinically blind NCL
patients and sighted control subjects were examined (I). The experiments were carried out in three
INCL patients (one girl and two boys, ages 6-11 years), four JNCL patients (one female and three
males, ages 13-28 years), and seven healthy drug-free control subjects (two women and five men, ages
18-27 years). All patients had been practically blind for years and all had neurological impairment. All
patients, except one man (patient 7), were mentally retarded and had epilepsy. All patients received
antiepileptic drugs, and JNCL patients received antioxidant therapy (Santavuori et al. 1988). Pupillary
light reflexes, noncorneal ERG, and VEPs to flashes of light were studied.
Each patient and control subject participated in two sessions. During the dim-light control session, the
individual melatonin profiles were determined. The samples were collected before midnight in ordinary
room light (50 to 200 lux) and after midnight in a dimly lit room (<10 lux). During the second session,
a 60-min light exposure (3000 lux) was applied during the latter half of the rising phase of the
melatonin production. The blood samples were collected every 60 minutes from 1900 to 0600 h and
an additional sample was taken 30 minutes after the beginning of the light exposure.
Suppression of melatonin through closed eyelids
The effect of bright light on melatonin through closed eyelids was studied by exposing the volunteers
to 2000-lux light during the rising phase of the melatonin secretion (II). Salivary melatonin levels were
measured in 8 healthy drug-free volunteers (3 males, 5 females, ages 20-53 years). The volunteers
came to the laboratory for 3 sessions: first for the determination of the control pattern of melatonin in
dim light with the eyes open, then for the 2000-lux light exposure either with the eyes open or closed.
The samples were collected every hour from 1900 to 0200 or 0300 h, before 2400 h in ordinary room
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light (50-200 lux) and after 2400 h in dim light (<10 lux). During the second and third sessions, the
2000-lux light for 60 min was applied during the rising phase of the melatonin synthesis determined
individually according to the control melatonin profiles. When the exposure occurred with the eyelids
closed, the eyelashes of the subjects were taped to the skin under the eyes so that the tape did not
cover the upper eyelids. The light exposure times were between 2400 and 0200 h, and during the
exposures the samples were collected at 15-min intervals.
Phase shift of melatonin rhythm by 500-lux light
In the first experiment the effect of moderate illuminance level on the melatonin rhythm was studied by
exposing the volunteers to 500-lux light at 2300 h for 60 min (III). Salivary melatonin levels were
measured in 7 volunteers (3 males and 4 females, ages 21-37 years). They were healthy and drug-free
students or personnel of the institute. On day 1 the control melatonin profiles were determined, day 2
was for rest, on day 3 the melatonin production was interrupted by a 60-min light exposure (from
2300 to 2400 h), and on day 4 the samples were collected as on day 1. Lighting was <100 lux until
2400 h. During the sleeping period (from 2400 to 0700 h) lighting was <0.1 lux. From 0700 to 1000 h
the illuminance was <100 lux. During the sessions, samples were collected every hour from 2000 to
1000 h, except at 0300 and 0500 h.
In the second experiment the effect of a moderate illuminance level on the melatonin rhythm was
studied by exposing the subjects to 500-lux light at matched exposure times during the latter half of
the rising phase of the melatonin production (III). Salivary melatonin levels were measured in 5
healthy volunteers (1 female and 4 male students, ages 18-19 years). On day 1, the samples were
collected every hour from 1800 to 1100 h under constant illumination of <10 lux. After a week, on
day 8, the 500-lux light exposure was from 2300 to 2400, from 2400 to 0100, or from 0100 to 0200 h
according to the individual melatonin profiles measured on the experimental control day 1. On day 8,
the samples were collected immediately before and after the light exposure and 0.5, 1 and 2 hours
before and after the exposure. On day 9, the samples were collected every hour from 1800 to 1100 h
as during day 1.
Phase shift of melatonin rhythm by light with concomitant exogenous melatonin
administration
The effect of bright light on the human melatonin rhythm was examined by exposing the subjects to
2000-lux light at matched exposure times during the latter half of the rising phase of the melatonin
production. The light-induced decrease of melatonin concentration was replaced with exogenous
melatonin in a placebo-controlled, single-blind, randomized study (IV). Salivary melatonin levels were
measured in 6 volunteers (1 male and 5 females, ages 20-52 years). They were healthy and drug-free
students or personnel of the institute. Both the placebo and melatonin parts of the study consisted of
three sessions: a control session, a light-exposure session and an after-light session. The lighting was
<10 lux in the laboratory. During the control and after-light session, samples were collected every
hour from 1800 to 1100 h. One week after the control session, the subjects came to the laboratory for
the light-exposure session. Placebo or 0.5 mg melatonin (supplied by Sigma Warrants, St. Louis, US;
prepared by the Pharmacy at Helsinki University Hospital, Helsinki, Finland) in gelatin capsules were
taken 60 min before the light exposure. The 2000-lux light exposure occurred from 2400 to 0100 or
from 0100 to 0200 h according to the control melatonin profiles.
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The effect of prolongation of dim morning light on the melatonin rhythm was also tested (IV). Salivary
melatonin levels were measured in 6 volunteers (2 males and 4 females, ages 20-55 years). They were
healthy and drug-free students or personnel of the institute. The subjects were in the laboratory two
consecutive nights from 1800 to 1100 h, and samples were collected every hour. The illuminance was
<10 lux during the experiment.
LIGHT SOURCES AND EXPOSURE PROCEDURES
In the patient study (I), take-along lamps were used to facilitate the experimental procedures involving
the NCL patients. The highest intensity achieved by these lamps was 3000 lux, measured at the
forehead of each subject (Chroma Meter CL-100, Minolta Camera Co., Ltd., Osaka, Japan). During
the exposures, the patients and control subjects were lying in bed and the lamps (fluorescent tubes,
11W, 2700K, Lival, Helsinki, Finland), forming a reflection area of 20 x 10 cm2, were placed in the
correct position (about 20 cm from the eyes). The penetration of light to the eyes was controlled as
follows. During the whole exposure time a researcher inspected the patient’s eyes. If the eyes were not
open, the experimenter opened them by hand every 2 minutes for 2 seconds. Two of seven patients
kept their eyes open all the time and thus two control subjects were exposed to light with the eyes
open. The eyes of the other five patients were opened by the researches and five control subjects
opened their eyes by themselves similarly every 2 minutes by request.
In the other studies (II-IV), the light source was a panel on a wall. It was composed of 16 True-Lite
fluorescent tubes (40W, 5500K), mounted vertically on a wall, and forming a luminant area 2.4 m
wide and 1.3 m high. In front of the tubes there was a white flashed opal glass for diffusing light evenly
over the panel. In order to achieve the desired illuminance at the eye level, the subjects were sitting at
the correct distance from the panel and they were instructed to gaze the light source all the time during
the exposures.
MEASUREMENT OF MELATONIN AND CHARACTERIZATION OF THE
PATTERNS
Radioimmunoassay
Melatonin was measured from saliva (II,III,IV) or serum (I) samples by the radioimmunological
method developed by Vakkuri and co-workers (1984) using radioiodinated melatonin as a tracer. This
method has earlier been validated for saliva samples, and the salivary levels have been 30-40% of the
levels in serum (Vakkuri 1985, Laakso et al. 1990). The properties of antiserum raised in rabbits by
immunization with bovine thyroglobulin conjugate of N-acetyl-5-methoxytryptophan as described by
Arendt and coworkers (1975) have been published previously (Laakso et al. 1988). The reference
samples were prepared from synthetic melatonin (Sigma, St. Louis, MO, US) dissolved in the assay
buffer over the range 1.95-1,000 pg/ml.
The nonspecific binding of the tracer was 5 to 6%. The least detectable concentration, defined as
apparent concentration at two standard deviations (SDs) from the counts at maximum binding, was
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smaller than the lowest standard. The intra-assay variability, calculated from the duplicate
measurements, was 4 to 10%. During the assays of this study the interassay variability, calculated as
SDs of the quality control samples, was 5 to 19% depending on the concentration.
Calculations of individual phase marker times and phase shifts
In order to characterize the individual melatonin patterns and to calculate the phase shifts (III,IV), the
half-rise and half-decline times were determined as follows: (i) peak level was calculated as the mean
of the three highest values of the pattern, (ii) baseline level was the mean of the three lowest values of
the pattern, (iii) half-maximal level was defined as the half-way point between the peak and baseline
level, and (iv) half-rise and half-decline times were estimated graphically from the drawings of the
individual raw data without smoothing the curves. They were the time points at which the half-
maximal level was reached in the ascending or descending part of the pattern, respectively. The
individual phase shifts were the differences of half-rise times or half-decline times between the two
patterns.
STATISTICS
The melatonin patterns were evaluated with two-way analysis of variance (ANOVA) for repeated
measures followed by parametric post tests (Tukey-Kramer or Bonferroni for selected pairs).
Logarithmic values of the data were used when Barlett’s test showed heterogeneity of variances.
Student’s t-test or paired t-test was used in evaluations of two groups of samples. Nonparametric
Wilcoxon test was chosen for calculations if the data were not normally distributed and did not fulfil
the criteria for parametric statistical tests. Spearman’s rank order correlation coefficients were
calculated to evaluate relationship between two groups of samples.
40
RESULTS
SUPPRESSING EFFECT OF LIGHT ON MELATONIN SECRETION
Bright light exposure in patients without conscious light perception
The effect of a 3000-lux, 60-min light pulse on melatonin levels was studied in control subjects and
NCL patients (I). The serum melatonin concentrations of all seven control subjects and six of seven
patients increased during the night. One patient’s (patient 6) melatonin pattern was abnormal, without
a clear maximum at nighttime. The data from this patient are included in the calculations. The ranges
of the highest levels were 67 to 181 ng/l (control subjects) and 21 to 164 ng/l (patients). In the control
subjects, the suppression of the average melatonin level by light seemed to be quite modest, but in the
patients, the effect of light was more evident. However, the average melatonin pattern during the dim-
light session differed significantly from that during the light-exposure session in both groups (controls:
session NS, time p<0.001, session x time p<0.02; patients: session NS, time p<0.001, session x time
p<0.001; two-way ANOVA). Bonferroni multiple comparisons test for selected pairs did not show
any differences in the dim-light melatonin levels between the control subjects and patients, but the
concentrations at the end of the light exposure were significantly lower in patients than control
subjects (p<0.05). The postlight level and the corresponding dim-light level of the patients were
significantly different from each other (p<0.01).
The 3000-lux light exposure suppressed melatonin in three of seven control subjects (in the two
control subjects with the eyes open during the exposure and in one who opened his eyes every 2
minutes for 2 seconds). The average postlight level was equal to the prelight level, but tended to be
lower than the corresponding control level (80%). The light exposure reduced melatonin
concentrations in all seven patients. The average level after the light pulse was 61% of the prelight
level and 51% of the corresponding level in the control session. The decrease of melatonin level by
light tended to be more marked in patients than control subjects (p=0.058, t-test). After one hour of
recovery in darkness, the average melatonin levels were close to the prelight values both in control
subjects and patients. When expressed in percentages of prelight values, they did not differ
significantly from each other. However, in the patients, the concentration remained clearly lower than
the corresponding control level (58%), but in the healthy subjects, the level was almost the same as
during the control session (88%). The recovered levels, expressed in percentages of the dim-light
control melatonin concentrations, were significantly lower in patients than control subjects (p=0.032,
t-test).
Bright light exposure in subjects with closed eyelids
The effect of a 2000-lux, 60-min light pulse on melatonin secretion was examined in volunteers with
the eyes closed (II). The salivary melatonin concentrations of all 8 subjects increased during the dim-
light control session. The range of the highest melatonin levels was 18-65 ng/l. The suppressive effect
of 2000-lux light was evident in all subjects when they were exposed to light with their eyes open
(control versus eyes open session: session p<0.02, time p<0.001, session x time p<0.001; two-way
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ANOVA). The average remaining concentration at the end of exposure was 45±14% (±SD) of the
prelight level and 30±18% of the corresponding control concentration. When the subjects kept their
eyes closed, the light exposure diminished the melatonin levels only in 2 of the 8 volunteers. In the
other 6 subjects they remained at the prelight level or continued to increase. The average remaining
concentration at the end of exposure with closed eyes was 121±61% of the prelight level and 78±24%
of the corresponding control concentration. The overall melatonin level, however, was lower during
the eyes-closed session than dim-light control session (session p<0.05, time p<0.005, session x time
NS; two-way ANOVA).
PHASE SHIFTING EFFECT OF LIGHT ON MELATONIN RHYTHM
Phase shift of melatonin rhythm by moderate illuminance
The effect of moderate illuminance (500 lux) for 60 min on the melatonin rhythm was examined in
healthy volunteers (III). The salivary melatonin concentration of all subjects increased during the dark
period, but the interindividual variation of peak levels was great (range 7-51 ng/l). In the first
experiment in which the light exposure occurred at the early or late rising phase of the pattern, the
average melatonin profile during the night following the exposure did not differ significantly from the
control profile (session, NS; time, p<0.001; session x time, NS; two-way ANOVA). In the second
experiment in which the exposure time was individually adjusted to the late rising phase, two-way
ANOVA suggested that the melatonin levels at some time points were significantly different, but the
overall melatonin levels did not differ (session, NS; time, p<0.001; session x time, p<0.01).
By combining the results of both experiments, the difference between the control and experimental
onset times was statistically significant in parametric (p<0.01, t-test) as well as in nonparametric
(p<0.005, Wilcoxon) testing. The delay of offset occurred in 7 of 12 subjects, but it was not
statistically significant (NS, t-test; NS, Wilcoxon test). The suppressive effect of the 500-lux light
exposure varied individually between 21 and 83% of the prelight level; the average suppression was
about half of the prelight level (56±18%). No significant correlation was found between the
percentage of the suppression and the magnitude of the delay of the melatonin onset (rs= -0.112,
Spearman’s correlation coefficient), but the delay of the melatonin offset was the greater the more the
melatonin level was suppressed (rs= +0.775, p<0.01).
Phase shift of melatonin rhythm by bright light with concomitant exogenous melatonin
administration
The effect of exogenous melatonin on a bright light pulse (2000 lux, 60 min) induced phase shift of the
melatonin rhythm was studied in healthy volunteers (IV). The salivary melatonin concentration of all
volunteers increased during the night. The interindividual variation of the highest levels was 18-71
ng/l. The mean melatonin profiles of the control sessions in the placebo and melatonin experiments
were similar (two-way ANOVA). The suppressive effect of the 2000-lux light exposure varied
individually between 44 and 80% of the prelight level; the average suppression was 64±14% of the
prelight level and 72±11% of the corresponding level in the control session. There was great
interindividual variation among the peak melatonin concentrations reached after the oral dosage of
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melatonin (range 39-1096 ng/l; mean 407 ng/l). There was no difference between the half-rise times of
the two control sessions (placebo versus melatonin session); nor did the half-decline times differ
between those sessions (NS, paired t-test). In the placebo experiment, there was a delay (mean delay
0.5 h) between the half-rise times of the control and after-light session in 5 of the 6 subjects, whereas
the half-rise times did not differ significantly between the sessions. In the melatonin experiment, the
half-rise times of the control and after-light session differed significantly from each other (p<0.005, t-
test; mean delay 0.8 h). The half-decline times (control versus after-light session) differed significantly
in both placebo (p<0.05, t-test; mean delay 0.7 h) and melatonin experiment (p<0.02, t-test; mean
delay 0.7 h).
The effect of the prolongation of dim morning light on the melatonin rhythm was studied in healthy
volunteers (IV). The interindividual variation of the highest melatonin levels was 24-52 ng/l. The mean
melatonin profiles of the two consecutive nights were similar (two-way ANOVA). The half-rise and
half-decline times did not differ between those nights (NS, t-test).
43
DISCUSSION
SUPPRESSING EFFECT OF LIGHT ON MELATONIN SECRETION
Bright light exposure in patients without conscious light perception
Study I shows that bright light is able to suppress melatonin secretion in INCL and JNCL patients
despite their degenerated retinas and visual failure, indicating that the photic pathway used by the
circadian system may be able to function in NCL patients without conscious light perception. This is in
line with the results of Czeisler and coworkers (1995) who described three patients who despite
different origins of blindness (retinopathy or optic neuropathy) and totally lost pupillary light reflexes
responded positively in a melatonin suppression test (~10 000-lux light exposure for 90 to 100
minutes). Furthermore, alterations in melatonin concentrations, body temperature, subjective
sleepiness and mood have been reported after a 2-week morning bright light intervention in a group of
blind as well as sighted subjects (Partonen et al. 1995).
In our study the suppression of melatonin by bright light (3000 lux, 60 minutes) was more distinct in
the patients than control subjects. It is possible that NCL patients are exceptionally sensitive to the
hypothalamic effects of light for some unknown reason. For instance, the degeneration of the retinas
induced by the NCL disease (Goebel et al. 1974, Tarkkanen et al. 1977) may affect neural and
pigment layers allowing more light to enter ocular vessels. Indeed, Oren (1996, 1997) has
hypothesized that the retina within its prominent blood vessels may be a primary site of
phototransduction by the aid of some blood-borne light-sensitive compounds.
However, the difference in the suppression between the patients and sighted subjects could be
explained by methodological factors as well: the eyes of the patients were opened by the researchers
whereas the control subjects opened their eyes themselves. We did not force the uncooperative
patients to keep their eyes closed during the intervals between the eye openings. Thus, some patients
might have opened their eyes during the intervals and received more light during the whole exposure
than the control subjects who kept their eyes closed and opened them only by request.
Another reason for the greater suppression in the patients might be their abnormal pupillary reflexes.
The pupil diameter may be a factor in the effectiveness of light stimuli to suppress melatonin (Gaddy et
al. 1993). Because of the slow pupillary reflex in six of the seven patients, more light may have
entered their retinas.
A third explanation for the difference might be provided by the different age ranges of the groups. For
ethical reasons, all control subjects were young adult volunteers, whereas four of seven patients were
children between 6 and 13 years of age. The transmission of light through the optic structures of the
eye changes somewhat with age (Lerman 1987, Brainard et al. 1993, Brainard et al. 1997). The
lenticular transmission of short wavelengths is especially reduced. Although the age difference
between the groups was not great, it is, at least theoretically, a source of error.
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A few studies suggest that extraretinal photoreception can participate in rhythm regulation in humans
(Campbell & Murphy 1998) and in rats (Jagota et al. 1999). However, there are also contradictory
results proposing that neither nonhuman mammals (Nelson & Zucker 1981, Ibuka 1987, Meijer et al.
1999, Yamazaki et al. 1999) nor humans (Lindblom et al. 2000) have nonocular circadian
photoreception. In any case, there is evidence against suppression of melatonin levels by skin
illumination in humans (Lockley et al. 1998, Hébert et al. 1999, Lindblom et al. in press) and in
hamsters (Yamazaki et al. 1999), indicating that in our study in INCL and JNCL patients the
suppression of melatonin was not induced by light exposure to the facial skin. This is supported by a
study of Czeisler and coworkers (1995) in which bright light suppressed melatonin secretion in two
blind subjects only when their eyes were uncovered.
The average suppression of melatonin in our healthy control subjects was quite slight compared with
the findings that illuminances as low as 300-500 lux were sufficient for a significant suppression of
melatonin levels (Bojkowski et al. 1987, McIntyre et al. 1989, Hashimoto et al. 1996, Aoki et al.
1998). Our result was probably due to five of the seven subjects opening their eyes only every 2
minutes, because closed eyelids may limit the amount of light entering to the hypothalamus and pineal
gland (II).
Blindness is one of the main symptoms in NCL patients. Degeneration of the retina with loss of
photoreceptors has been found in both the INCL and JNCL disease (Haltia et al. 1973, Goebel et al.
1974, Tarkkanen et al. 1977, Spalton et al. 1980, Traboulsi et al. 1987, Goebel et al. 1988). Based on
ophthalmological and neurophysiological findings, the blindness in INCL and JNCL patients can be
both of retinal and cortical origin (Raitta & Santavuori 1973, Pampiglione & Harden 1977, Santavuori
1988, Santavuori et al. 1988, Horiguchi & Miyake 1992, Seeliger et al. 1997, Vanhanen et al. 1997,
Weleber 1998). All our patients responded to light with pupillary constriction, although the reflex
could be considered normal only in one patient. Despite these deficiences and abnormalities in visual
function, the suppression of melatonin by light was clearly apparent in each patient. The findings could
be interpreted as evidence for intact retinohypothalamic pathways and sympathetic connections to the
pineal gland inspite of the affected visual pathways.
Although the retinal damage induced by the NCL disease can be determined on the basis of autopsies,
the present study does not provide information about the quality of the retinal cells mediating light
information to the melatonin regulating system, because we have no knowledge of the patients' retinal
structure at the time of the experiment.
In fact, it is not at all clear what kinds of retinal receptors are involved in circadian timekeeping.
Originally they were thought to be classical photoreceptors, rods and cones (Thiele & Meissl 1987) or
only rhodopsin-like pigments (Takahashi et al. 1984, Brainard et al. 1985, Bronstein et al. 1987).
More recently, the role of traditional photoreceptors have been challenged by studies showing
circadian responses to light without rods, or without cones, or only with fragments of photoreceptors
(Foster et al. 1993, Provencio et al. 1994, Ruberg et al. 1996, Lucas & Foster 1999). Nevertheless, it
seems that there might be some unidentified retinal light-sensitive elements involved in circadian
function (Yoshimura & Ebihara 1996, Freedman et al. 1999, Huerta et al. 1999, Lucas et al. 1999).
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Furthermore, compensatory structures subserving photic functions (Cooper et al. 1993) might be
recruited by blindness. Perhaps a distinct subset of retinal ganglion cells working as a unique
communicator for the circadian timing system (Moore et al. 1995) elaborates some kinds of coping
mechanisms generated by the degenarative niche.
In our recent study in NCL patients, disturbances in the daily melatonin and cortisol rhythms occurred
only in a minority of the patients and only at an advanced state of the disease (Heikkilä et al. 1995),
suggesting that light may entrain the hormonal rhythms despite the blindness. Although the sleep-wake
rhythms were not normal in the patients, it seems that light may have an impact on other rhythmical
outputs. This may be due to a direct effect of light on the hypothalamus and autonomic functions as
proposed by studies showing e.g. that the heart rate (Warren et al. 1994, Scheer et al. 1999) or the
menstrual cycle length (Rex et al. 1997) respond to light.
Taken together, the present results propose that the ability of light to reach the hypothalamus and
regulate neuroendocrine functions may persist long after a visual failure appears. The quality of the
photoreceptive cells needed for the transmission of light from the eyes to the circadian timing system is
not known. However, it could be proposed on the basis of the present study that the traditional retinal
photoreceptors are not essential or that only a small number of these cells are needed for the circadian
function in humans, as is also suggested by animal studies. Moreover, there may be some unidentified
pathways through which the circadian effects of light may be transmitted to the human body. Thus,
taking care of proper environmental lighting conditions may enhance the well-being of those blind
people in whom light is able to penetrate, at least to some extent, the optical structures.
Bright light exposure in subjects with closed eyelids
Study II shows that melatonin concentrations decreased only in 2 of the 8 volunteers during the light-
exposure sessions (2000 lux, 60 min) with the eyes closed, although the suppressive effect was evident
in all subjects with their eyes open. To my knowledge, a light-induced reduction of melatonin levels
through closed eyelids has not been reported earlier. However, it has been observed that 6-17-lux
(photopic) or 28-86-lux (scotopic) illuminance of monochromatic light of 509 nm is sufficient to
suppress melatonin within 60 min in humans examined in specially controlled conditions when the
pupils have been dilated, the volunteers' heads kept motionless and the light beam directed uniformly
on the retina (Brainard et al. 1988). In other studies, higher illuminances (300 to 500 lux) have been
needed to suppress melatonin levels significantly (Bojkowski et al. 1987, McIntyre et al. 1989,
Hashimoto et al. 1996, Aoki et al. 1998) and in earlier studies light has not been observed to suppress
melatonin (Vaughan et al. 1976, Jimerson et al. 1977, Vaughan et al. 1979, Åkerstedt et al. 1979).
The variation of the results is probably caused by differences in the gaze control of subjects during the
light exposures. Indeed, the direction of gaze is one of the main factors influencing the amount of light
reaching the retina, and gaze aversion can reduce both the illuminated corneal and retinal area
(Dawson & Campbell 1990, Gaddy 1990).
46
The transmittance of light through human eyelids has been found to be 10-15% in the red end of the
spectrum at 700 nm declining to approximately 3% below 600 nm in measurements conducted in vivo
(Moseley 1988, Robinson et al. 1991). In our study, the varying results could be explained so that in
the two responders the transmitted amount of light produced a retinal illuminance that exceeded the
lowest effective limit for suppression whereas in the other subjects less light was transmitted or their
individual thresholds to respond were higher.
Some methodological reasons may also explain the different responses in the subjects. Our subjects
were asked to gaze directly at the light panel during the entire 60-min exposure. When exposed to
light with the eyes open, the behavior of the subjects could be controlled by the researcher. When the
exposure occurred with closed eyelids, the head position could be controlled but the gaze behavior
could not. For instance, the so called Bell's phenomenon (palpebro-oculogyric reflex), in which
forcible closing of the eyelids causes the eyes to turn up and out (Newell & Ernest 1974), might have
affected the admission of light to the retina in some subjects.
The degree of skin pigmentation could not have caused any major variation in the penetration of light
because all subjects were blond northern people. Both responders were young females with relatively
high peak levels of melatonin. Therefore, it could be suggested that melatonin suppression through
closed eyelids occurred also in the low-secretors but it was so small that it was not detected with the
measurement method applied. However, this explanation does not seem valid since the young female
with the highest melatonin peak did not respond. The interindividual variation might also have resulted
from the subjects being exposed at different circadian phases. This explanation is not convincing either,
because it has been shown that sensitivity of the human melatonin synthesis to light remains unchanged
during the rising phase (Laakso et al. 1994c).
The present study shows that closed eyelids can induce interindividual variation in melatonin
suppression induced by 2000-lux light. In ambulatory measurements, usual room illumination has been
reported to be 150-180 lux (Koller et al. 1993) and people in the modern industrialized society spend
>90% of their time at ambient illuminance levels below 1000 lux (Savides et al. 1986). This indicates
that the common indoor conditions, where the illuminance is usually much lower than 2000 lux, do not
provide enough light to suppress melatonin secretion in humans with closed eyelids. However, it is
possible that high illuminances (e.g. 10 000 lux) can be effective also through closed eyelids, for
instance during sleeping.
The present finding is in agreement with the studies indicating that light exposure without penetration
of light via the eyes has no effect on melatonin levels in humans (Czeisler et al. 1995, Lockley et al.
1998, Hébert et al. 1999, Lindblom et al. in press). However, light may influence performance,
daytime alertness and mood (Campbell et al. 1995, Daurat et al. 1996, Partonen & Lönnqvist 1998)
even when applied to sleeping subjects (Avery et al. 1994, Wirz-Justice et al. 1997), most probably by
some unknown mechanisms.
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PHASE SHIFTING EFFECT OF LIGHT ON MELATONIN RHYTHM
Phase shift of melatonin rhythm by moderate illuminance
Study III indicates that a single light pulse of relatively low intensity (500 lux) and short duration (60
min) induces interruption of melatonin secretion and delays the melatonin rhythm one day after the
exposure. Furthermore, the increase of background illuminance from <1 lux to <100 lux in the
morning suppressed or stopped the melatonin synthesis, and the mean melatonin offset time was not
delayed. The intensity of the exposure used in the present study was clearly lower than the intensities
previously thought to be required to phase shift or entrain the circadian pacemaker in humans (Lewy
et al. 1984, Lewy et al. 1985, Lewy et al. 1987, Wever 1989).
More recently, it has been confirmed that light of domestic intensity (150-500 lux) produces phase
shifts of the human melatonin (Zeitzer et al. 1997, Boivin & Czeisler 1998) and body temperature
rhythm (Waterhouse et al. 1998), proposing together with the present results that ordinary indoor
room light could exert physiological effects on circadian functions of individuals living most of the
time in artificial lighting conditions. If this proposition holds true, the melatonin signal can be
considered a sensitive marker of environmental lighting conditions, even in urbanized people.
In the present study, there is a methodological factor which has to be considered when assessing the
results. Repeated (during 3 consecutive days) light exposures of high intensity (∼5000-10000 lux) and
of long duration (5-6 hours) have been shown to induce changes in the melatonin rhythm even during
daytime (Hashimoto et al. 1997, Jewett et al. 1997). In the present study the volunteers were allowed
to leave the laboratory during the intervals of the sessions. However, they were instructed to avoid
exceptionally bright light exposures and asked not to take naps during daytime hours. In the PRCs to
light, the phase shifts of the human melatonin or temperature rhythm have been small or absent during
daytime (Minors et al. 1991, Van Cauter et al. 1994). Moreover, if any shifts occur during daytime
hours, light may induce phase advances rather than delays of the melatonin rhythm (Dijk et al. 1989,
Burešová et al. 1991, Van Cauter et al. 1994), indicating that the phase delays of the melatonin
rhythm in the present study were induced by the experimental light pulses. This is supported by the
results of Study IV of this thesis, in which the conditions were similar to those of the present study,
showing that the mean melatonin patterns of two consecutive nights were equal despite the subjects
being away from the laboratory during the day between the sessions. In addition, in Study IV no shifts
of the melatonin rhythm were found between the two control sessions with intervals of 4 to 9 weeks.
Taken together, the above findings could be interpreted as evidence that extraneous light did not
significantly influence the results, and that the changes observed in the melatonin levels and rhythms
were induced by the 500-lux moderate illuminance.
The present study and other studies conducted later (Zeitzer et al. 1997, Boivin & Czeisler 1998,
Waterhouse et al. 1998) propose that human body temperature and melatonin rhythms are influenced
by light of moderate intensity. At present, it is not known whether other human rhythms, e.g. sleep-
wake rhythms, are adjusted by light of domestic intensity. It is possible that the simple rhythms of
temperature and melatonin are mainly adjusted by lighting, while in the regulation of more complex
rhythms, e.g. performance and rest-activity rhythms, repeated or stronger signals of light are required.
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Phase shift of melatonin rhythm by bright light with concomitant exogenous melatonin
administration
In Study IV a 60-min, 2000-lux light pulse during the rising phase of melatonin synthesis delayed the
average half-decline and half-rise times equally in the placebo and melatonin replacement experiments.
This is consistent with the study of Yellon and Hilliker (1994) who used a similar paradigm and
showed that a melatonin injection to hamsters before the light pulse failed to alter the effect of light on
the melatonin rhythm. The inefficacy of melatonin to counteract the light-induced phase shift in
humans has been confirmed by Kräuchi and coworkers (1997a) who showed that the hypothermic
effect of late evening exogenous melatonin does not block the phase delay induced by a concurrent
5000-lux light exposure in humans. Quite recently, in a study by Kennaway and Rowe (2000),
stimulation of endogenous melatonin production by isoproterenol failed to block the phase shifting
effect of a light exposure on melatonin metabolite excretion in rats. These findings suggest that the
suppression of melatonin by light stimulation is not responsible for the phase delay in melatonin
production.
On the other hand, slightly different experimental paradigms have disclosed some interactions between
melatonin and light exposure. For instance, the phase advance of melatonin offset was inhibited and
the phase advance of melatonin onset was enhanced by a 3000-lux light stimulus with concomitant
melatonin administration in humans (Cagnacci et al. 1997). In addition, Benloucif and coworkers
(1999) found that combined administration of melatonin and light in mice affected circadian timing in a
complex manner which could not be predicted by summing the effects of  melatonin and light
treatments given separately.
Melatonin has binding sites in the circadian clock of the SCN (Vanecek et al. 1987, Reppert et al.
1988, Weaver et al. 1993, Morgan et al. 1994) and melatonin is able to reset the discharge rate
rhythm of the pacemaker within two windows of sensitivity (McArthur et al. 1991, McArthur et al.
1997). On the basis of the PRC to exogenous melatonin, the optimal time to produce a phase delay
and advance varies depending on the circadian time (Lewy & Sack 1997, Lewy et al. 1998a). Thus,
the efficacy of melatonin action depends on the phase of the circadian timing system. In the above
studies, the variable circadian time of melatonin administration and other methodological factors (e.g.
dose, administration route, interval between melatonin and light, species) may explain the
discrepancies between the results. However, on the basis of the current knowledge there is insufficient
evidence to determine the precise conditions under which melatonin interacts with light exposure.
Therefore, further studies are needed to clarify the possible influences that the absence or presence of
interactions between melatonin and light might have on the rhythm regulation.
There were two intervening factors that might have influenced the results of the present study: the
prolongation of dim light in the morning and the abnormally high melatonin levels still in the morning
due to the ingestion of the melatonin capsule. Theoretically, both factors could have potentiated the
effect of the light exposure. The prolongation of dim light was necessary to avoid a premature
cessation of melatonin secretion by light. In the additional control experiment, however, the
prolongation of dim light in the morning did not produce any systematic phase shift within one day.
Thus, the dim morning light did not seem to be a source of error in the main experiment of the present
study.
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The dose of melatonin used in the present study (0.5. mg) is considered 'physiological' (Lewy et al.
1992) in the sense that it produces plasma levels and a peak duration comparable to the endogenous
levels and peak duration. This dose was used to ensure that the suppression caused by the light
exposure would be sufficiently replaced. In all subjects, the peak levels of melatonin after the oral
dosage were higher than the endogenous peak levels. In the morning, 10-12 hours after the ingestion,
the melatonin concentrations were still somewhat higher than the values measured after the placebo.
Based on the PRC to melatonin (Lewy et al. 1992, Lewy et al. 1998a), it seems that this oral dose of
melatonin does not produce any major phase shifts when ingested during the period corresponding to
the rising phase of the endogenous melatonin synthesis. Therefore, it could be proposed that the delay
of the melatonin rhythm was not a consequence of the somewhat elevated melatonin levels in the
morning. This indicates that the light exposure preceding the peak time of melatonin secretion was
responsible for the phase delay both in the placebo and melatonin experiments.
In conclusion, the present study and the study by Kräuchi and coworkers (1997a) with similar
paradigms indicate that the delaying effect of light on the human circadian rhythms do not depend on
the melatonin concentration in the circulation. Thus, light is able to influence the circadian rhythms
independently of melatonin levels in the body, indicating that melatonin suppression is not an essential
part of the mechanism by which light modulates our circadian timing system.
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CONCLUSIONS
A few decades ago it was still thought that light had no impact on the circadian rhythms in humans.
The present findings together with other studies indicate that light is the primary external cue
regulating our circadian functions. Melatonin acts as a reliable neuroendocrine messenger of
environmental lighting conditions, but the phase shifting effect of light on circadian rhythms can be
independent of the melatonin concentration in the circulation.
I) A bright light exposure was able to suppress melatonin secretion in blind
neuronal ceroid lipofuscinosis patients with degenerated retinas, proposing that
the ability of light to reach the hypothalamus and regulate neuroendocrine
functions can persist independently of the visual failure.
II) A bright light exposure induced a decrease in melatonin concentrations only in a
minority of volunteers with closed eyelids. Thus, closed eyelids (e.g. during
sleep) significantly limit the transmission of light to the circadian timing system.
III) A single light pulse of moderate room illuminance induced an interruption of
melatonin secretion and shifted the phase of the melatonin rhythm. Thus,
melatonin acts as a sensitive marker of environmental lighting in everyday
conditions.
IV) A bright light pulse during the rising phase of the melatonin synthesis delayed
the melatonin rhythm irrespective of concomitant placebo or melatonin
administration. This indicates that suppression of melatonin is not essential for
the phase shifting mechanisms of light.
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